



06/17/97

418 201 A

DOCKET NO.: ISIS-2508

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Anticipated Classification of  
this application:

Phillip D. Cook

Class: 536 Subclass: 023

For: PNA-DNA-PNA-CHIMERIC MACROMOLECULES

Prior Application


Examiner: Christopher S.F. Low

Art Unit: 1804

"Express Mail" Label No. EM405755035US

Date of Deposit June 17, 1997 *DS*

I hereby certify that this paper is being deposited with the  
United States Postal Service "Express Mail Post Office to  
Addressee" service under 37 CFR 1.10 on the date  
indicated above and is addressed to the Assistant  
Commissioner for Patents, Washington, D.C. 20231.

  
Typed Name: Bob Inforzato

## BOX PATENT APPLICATION

Assistant Commissioner for Patents  
Washington, D.C. 2023137 C.F.R. §1.60 TRANSMITTAL LETTER

Sir:

This is a request for filing a

( ) Continuation (XX) Divisional application under  
37 CFR 1.60, of pending prior application Serial No. 08/158,352,  
filed on November 24, 1993 of Phillip D. Cook entitled PNA-DNA-  
PNA-CHIMERIC MACROMOLECULES.

1. (XX) Enclosed is a copy of the prior application, including  
the oath or declaration as originally filed.

I hereby verify that the attached papers comprise  
a true copy of the prior application Serial No.  
08/158,352, as originally filed on November 24,  
1993, and that no amendments referred to in the  
Oath or Declaration filed to complete the prior  
application introduced new matter therein.

The filing fee is calculated below on the basis of claims as filed in the prior application, less any claims cancelled or including any claims added by amendment listed below:

			SMALL ENTITY			OTHER THAN SMALL ENTITY	
For:	No. Filed	No. Extra	Rate	Fee	OR	Rate	Fee
BASIC FEE				\$385	OR		\$770
Total Claims	23- 20 =	0	x \$11=	\$33	OR	x \$22=	\$
Indep. Claims	3- 3 =	0	x \$40=	\$0	OR	x \$80=	\$0
First Presentation Multiple Dependent Claims			+\$130=	\$0	OR	+\$260=	\$0
TOTAL				\$418			\$

2. ( ) Verified Statement Claiming Small Entity Status is enclosed herewith.
3. ( ) Verified Statement Claiming Small Entity Status was filed in the parent case.
4. ( ) Please charge my Deposit Account No. 23-3050 in the amount of \$\_\_\_\_\_. This sheet is attached in triplicate.
5. (XX) A check in the amount of \$418.00 is attached. Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.
6. (XX) The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 23-3050. This sheet is attached in triplicate.
  - (XX) Any additional filing fees required under 37 CFR 1.16 including fees for presentation of extra claims.
  - (XX) Any additional patent application processing fees under 37 CFR 1.17 and under 37 CFR 1.20(d).

7. (XX) The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. 23-3050. This sheet is attached in triplicate.
- (XX) Any patent application processing fees under 37 CFR 1.17 and under 37 CFR 1.20(d).
- ( ) The issue fee set in 37 CFR 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR 1.311(b).
- (XX) Any filing fees under 37 CFR 1.16 including fees for presentation of extra claims.
8. ( ) Cancel in this application original claims \_\_\_\_\_ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
9. (XX) Amend the specification by inserting before the first line the sentence: --This is a ( ) continuation, (XX) division, of application Serial No. 08/158,352, filed November 24, 1993.--
10. ( ) Formal drawings/photographs will be submitted when requested by the United States Patent and Trademark Office.
11. ( ) Please abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file. (May only be used if signed by person authorized by 37 CFR 1.138 and before payment of the base issue fee.)
12. ( ) Priority of application Serial No. \_\_\_\_\_ filed on \_\_\_\_\_ in \_\_\_\_\_ (country) is claimed under 35 U.S.C. Section 119.
- ( ) The certified copy has been filed in prior application Serial No. \_\_\_\_\_, filed \_\_\_\_\_.
13. (XX) The prior application is assigned of record to ISIS Pharmaceuticals Inc. 2280 Faraday Avenue, Carlsbad, CA 92008.
14. ( ) Copy of the Assignment(s) of the invention and separate Form(s) 1595 for each Assignment will be submitted upon receipt of the Official Filing Receipt.

15. (XX) The power of attorney in the prior application is to John W. Caldwell and Joseph Lucci, Registration No. 28,937 and 33,307, ADDRESS: WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS LLP One Liberty Place - 46th Floor Philadelphia, PA 19103

(XX) The power appears in the original papers in the prior application.

( ) Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.

16. (XX) As appointment of associate attorneys and/or agents with full power to prosecute this application and to transact all business in the Patent Office connected therewith, please recognize the following:

Robert B. Washburn	Registration No. 16,574
Richard E. Kurtz	Registration No. 19,263
John J. Mackiewicz	Registration No. 19,709
Norman L. Norris	Registration No. 24,196
Albert W. Preston, Jr.	Registration No. 25,366
Dale M. Heist	Registration No. 28,425
Philip S. Johnson	Registration No. 27,200
John W. Caldwell	Registration No. 28,937
Gary H. Levin	Registration No. 28,734
Steven J. Rocci	Registration No. 30,489
Dianne B. Elderkin	Registration No. 28,598
Francis A. Paintin	Registration No. 19,386
John P. Donohue, Jr.	Registration No. 29,916
Henrik D. Parker	Registration No. 31,863
Suzanne E. Miller	Registration No. 32,279
Lynn B. Morreale	Registration No. 32,842
Michael P. Dunnam	Registration No. 32,611
Michael D. Stein	Registration No. 34,734
Albert J. Marcellino	Registration No. 34,664
David R. Bailey	Registration No. 35,057
John L. Knoble	Registration No. 32,387
Michele K. Herman	Registration No. 35,893
Barbara L. Mullin	Registration No. 38,250
Ken I. Yoshida	Registration No. 37,009
Mark DeLuca	Registration No. 33,229
Steven B. Samuels	Registration No. 37,711
Lynn A. Malinoski	Registration No. 38,788
Lori Y. Beardell	Registration No. 34,293
Doreen Yatko Trujillo	Registration No. 35,719
Michael P. Straher	Registration No. 38,325
Paul K. Legaard	Registration No. 38,534
Kevin M. Flannery	Registration No. 35,871
David A. Cherry	Registration No. 35,099


Anthony J. Rossi                      Registration No. 24,053  
D. Jennings Meincke                Registration No. 36,606  
Michael L. Korniczky                Registration No. 37,661  
Michael J. Swope                    Registration No. 38,041  
Edward D. Grieff                    Registration No. 38,898  
Gail Ann Dalickas                  Registration No. P40,979

and

Herb Boswell                        Registration No. 27,311  
Laurel Bernstein                    Registration No. 37,280  
Andrew E. Granston                Registration No. 38,473

17. ( ) A preliminary amendment is enclosed. Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.
18. ( ) A Petition for Extension of Time has been filed in the parent application, Serial No. \_\_\_\_\_ filed \_\_\_\_\_. A copy of the Petition for Extension of Time is enclosed.
19. (XX) Enclosed is a Statement to Support Filing and Submission of DNA/Amino Acid Sequences in Accordance with 37 CFR §§ 1.821 through 1.825.
- ( ) Enclosed is a Letter of Reference to Computer Readable Form.

Date: June 17, 1997

  
\_\_\_\_\_  
Joseph Lucci  
Registration No. 33,307

WOODCOCK WASHBURN KURTZ  
MACKIEWICZ & NORRIS LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
(215) 568-3100

## COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and

I verily believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **PNA-DNA-PNA Chimeric Macromolecules** the specification of which:

( ) is attached hereto.

(XX) was filed on November 24, 1993 as Application Serial No. 08/158,352.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to the patentability of this application in accordance with 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of any application on which priority is claimed:

Country	Number	Date Filed	Priority Claimed
<u>PCT</u>	<u>US92/11339</u>	<u>12/23/92</u>	<u>X</u>

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status (patented, pending)
<u>814,961</u>	<u>12/24/91</u>	<u>Pending</u>

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: **John W. Caldwell** and **Joseph Lucci**, Registration Nos. **28,937** and **33,307** of the firm of **WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS**, One Liberty Place - 46th Floor, Philadelphia, Pennsylvania 19103, and **Herb Boswell** and **Laurel Bernstein**, Registration Nos. **27,311** and **P37,280**, of **ISIS Pharmaceuticals**, 2280 Faraday Avenue, Carlsbad, California 92008.

Address all telephone calls and correspondence to:

**Joseph Lucci**  
**WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS**  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone No. 215-568-3100.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the

United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1	Full Name Phillip Dan Cook	Inventor's Signature <i>Phillip Dan Cook</i>	Date 2/22/74
	Residence Carlsbad, CA 92009		Citizenship U.S.A.
	Post Office Address 7340 Bolero Street		
2	Full Name	Inventor's Signature	Date
	Residence		Citizenship
	Post Office Address		
3	Full Name	Inventor's Signature	Date
	Residence		Citizenship
	Post Office Address		
4	Full Name	Inventor's Signature	Date
	Residence		Citizenship
	Post Office Address		
5	Full Name	Inventor's Signature	Date
	Residence		Citizenship
	Post Office Address		



## COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and

I verily believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **PNA-DNA-PNA Chimeric Macromolecules** the specification of which:

(xx) is attached hereto.

( ) was filed on \_\_\_\_\_ as Application Serial No. \_\_\_\_\_ and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to the patentability of this application in accordance with 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of any application on which priority is claimed:

Country	Number	Date Filed	Priority Claimed
PCT	US92/11339	12/23/92	X
_____	_____	_____	_____
_____	_____	_____	_____

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status (patented, pending)
<u>814,961</u>	<u>12/24/91</u>	<u>Pending</u>
<u>                    </u>	<u>                    </u>	<u>                    </u>
<u>                    </u>	<u>                    </u>	<u>                    </u>

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: **John W. Caldwell and Joseph Lucci**, Registration Nos. 28,937 and 33,307 of the firm of **WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS**, One Liberty Place - 46th Floor, Philadelphia, Pennsylvania 19103, and **Herb Boswell and Laurel Bernstein**, Registration Nos. 27,311 and P37,280, of **ISIS Pharmaceuticals**, 2280 Faraday Avenue, Carlsbad, California 92008.

Address all telephone calls and correspondence to:

**Joseph Lucci**  
**WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS**  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone No. 215-568-3100.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the

United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1	Full Name Phillip Dan Cook	Inventor's Signature	Date
	Residence 7340 Bolero Street Carlsbad, CA 92009	Citizenship U.S.A.	
	Post Office Address Same As Above		
2	Full Name	Inventor's Signature	Date
	Residence	Citizenship	
	Post Office Address		
3	Full Name	Inventor's Signature	Date
	Residence	Citizenship	
	Post Office Address		
4	Full Name	Inventor's Signature	Date
	Residence	Citizenship	
	Post Office Address		
5	Full Name	Inventor's Signature	Date
	Residence	Citizenship	
	Post Office Address		

089740649

**PNA-DNA-PNA CHIMERIC MACROMOLECULES****CROSS REFERENCE TO RELATED APPLICATIONS**

5 This application is a continuation-in-part of my prior application serial number US92/11339, filed December 23, 1992, entitled "Gapped 2' Modified Oligonucleotides", that in turn is a continuation-in-part to my prior application serial number 814,961, filed December 24, 1991, entitled "Gapped 2' Modified Oligonucleotides," both of which are commonly assigned with this application. This application is further related to  
10 application serial number 088,658, filed July 2, 1993, entitled "Higher Order Structure and Binding of Peptide Nucleic Acids, commonly assigned in part with this application. That application is a continuation-in-part of application serial number 054,363, filed April 26, 1993, entitled "Novel Peptide  
15 Nucleic Acids," which in turn is a continuation-in-part of application PCT EP/91/01219, filed May 19, 1992. The disclosures of each of these applications are herein incorporated by reference.

**FIELD OF THE INVENTION**

20 This invention is directed to the synthesis and use of chimeric molecules having a PNA-DNA-PNA structure wherein each "PNA" is a peptide nucleic acid and the "DNA" is a phosphodiester, phosphorothioate or phosphorodithioate 2'-deoxyoligonucleotide. In a cell, a cellular extract or a RNase H  
25 containing diagnostic test system, a chimeric macromolecule of the invention having a base sequence that is hybridizable to a

088734 05139  
05/29/93

RNA target molecule can bind to that target RNA molecule and elicit a RNase H strand cleavage of that RNA target molecule.

#### BACKGROUND OF THE INVENTION

It is well known that most of the bodily states in mammals including most disease states, are effected by proteins. Such proteins, either acting directly or through their enzymatic functions, contribute in major proportion to many diseases in animals and man. Classical therapeutics has generally focused upon interactions with such proteins in an effort to moderate their disease causing or disease potentiating functions. Recently, however, attempts have been made to moderate the actual production of such proteins by interactions with messenger RNA (mRNA) or other intracellular RNA's that direct protein synthesis. It is generally the object of such therapeutic approaches to interfere with or otherwise modulate gene expression leading to undesired protein formation.

Antisense methodology is the complementary hybridization of relatively short oligonucleotides to single-stranded RNA or single-stranded DNA such that the normal, essential functions of these intracellular nucleic acids are disrupted. Hybridization is the sequence specific hydrogen bonding via Watson-Crick base pairs of the heterocyclic bases of oligonucleotides to RNA or DNA. Such base pairs are said to be complementary to one another.

Naturally occurring events that provide for the disruption of the nucleic acid function, as discussed by Cohen in *Oligonucleotides: Antisense Inhibitors of Gene Expression*, CRC Press, Inc., Boca Raton, Fl (1989) are thought to be of at least two types. The first is hybridization arrest. This denotes the terminating event in which an oligonucleotide inhibitor binds to a target nucleic acid and thus prevents, by simple steric hindrance, the binding of essential proteins, most often ribosomes, to the nucleic acid. Methyl phosphonate oligonucleotides (see, e.g., Miller, et al., *Anti-Cancer Drug Design* 1987, 2, 117) and  $\alpha$ -anomer oligonucleotides are the two

most extensively studied antisense agents that are thought to disrupt nucleic acid function by hybridization arrest.

In determining the extent of hybridization arrest of an oligonucleotide, the relative ability of an oligonucleotide to bind to complementary nucleic acids may be compared by determining the melting temperature of a particular hybridization complex. The melting temperature ( $T_m$ ), a characteristic physical property of double helixes, denotes the temperature in degrees centigrade at which 50% helical (hybridized) versus coil (unhybridized) forms are present.  $T_m$  is measured by using the UV spectrum to determine the formation and breakdown (melting) of hybridization. Base stacking which occurs during hybridization, is accompanied by a reduction in UV absorption (hypochromicity). Consequently a reduction in UV absorption indicates a higher  $T_m$ . The higher the  $T_m$ , the greater the strength of the binding of the strands. Non-Watson-Crick base pairing, i.e. base mismatch, has a strong destabilizing effect on the  $T_m$ .

The second type of terminating event for antisense oligonucleotides involves the enzymatic cleavage of the targeted RNA by intracellular RNase H. The mechanism of such RNase H cleavages requires that a 2'-deoxyribofuranosyl oligonucleotide hybridize to a targeted RNA. The resulting DNA-RNA duplex activates the RNase H enzyme; the activated enzyme cleaves the RNA strand. Cleavage of the RNA strand destroys the normal function of the RNA. Phosphorothioate oligonucleotides are one prominent example of antisense agents that operate by this type of terminating event. For a DNA oligonucleotide to be useful for activation of RNase H, the oligonucleotide must be reasonably stable to nucleases in order to survive in a cell for a time sufficient for the RNase H activation.

Several recent publications of Walder, et al. further describe the interaction of RNase H and oligonucleotides. Of particular interest are: (1) Dagle, et al., *Nucleic Acids Research* 1990, 18, 4751; (2) Dagle, et al., *Antisense Research And Development* 1991, 1, 11; (3) Eder, et al., *J. Biol. Chem.*

1991, 266, 6472; and (4) Dagle, et al., *Nucleic Acids Research* 1991, 19, 1805. In these papers, Walder, et al. note that DNA oligonucleotides having both unmodified phosphodiester internucleoside linkages and modified, phosphorothioate internucleoside linkages are substrates for cellular RNase H. Since they are substrates, they activate the cleavage of target RNA by the RNase H. However, the authors further note that in *Xenopus* embryos, both phosphodiester linkages and phosphorothioate linkages are also subject to exonuclease degradation. Such nuclease degradation is detrimental since it rapidly depletes the oligonucleotide available for RNase H activation. As described in references (1), (2), and (4), to stabilize their oligonucleotides against nuclease degradation while still providing for RNase H activation, Walder, et al. constructed 2'-deoxy oligonucleotides having a short section of phosphodiester linked nucleotides positioned between sections of phosphoramidate, alkyl phosphonate or phosphotriester linkages. While the phosphoramidate containing oligonucleotides were stabilized against exonucleases, in reference (4) the authors noted that each phosphoramidate linkage resulted in a loss of 1.6°C in the measured  $T_m$  value of the phosphoramidate containing oligonucleotides. Such decrease in the  $T_m$  value is indicative of an undesirable decrease in the hybridization between the oligonucleotide and its target strand.

Other authors have commented on the effect such a loss of hybridization between an antisense oligonucleotide and its targeted strand can have. Saison-Behmoaras, et al., *EMBO Journal* 1991, 10, 1111, observed that even through an oligonucleotide could be a substrate for RNase H, cleavage efficiency by RNase H was low because of weak hybridization to the mRNA. The authors also noted that the inclusion of an acridine substitution at the 3' end of the oligonucleotide protected the oligonucleotide from exonucleases.

United States patent 5,149,797 to Pederson et. al., that issued on September 22, 1992 describes further oligonucleotides that operate by a RNase H mechanism. The oligonucleotides as claimed in this patent consist of an internal

segment composed of phosphorothioate nucleotides flanked by methyl phosphonate, phosphoromorpholidates, phosphoropiperazidates or phosphoramidates. Since all of the components of these oligonucleotides, i.e. phosphorothioate, methyl phosphonates, phosphoromorpholidates, phosphoropiperazidates or phosphoramidates when used as oligonucleotide linkages individually decrease the hybridization between the oligonucleotide and its target strand, the comments of Saison-Behmoaras et al., could be equally applicable to the oligonucleotides described in this patent.

While it has been recognized that cleavage of a target RNA strand using an antisense oligonucleotide and RNase H would be useful, nuclease resistance of the oligonucleotide and fidelity of the hybridization are also of great importance. Heretofore, there have been no suggestion in the art of methods or materials that could both activate RNase H while concurrently maintaining or improving hybridization properties and providing nuclease resistance even though there has been a long felt need for such methods and materials. Accordingly, there remains a long-felt need for such methods and materials.

#### OBJECTS OF THE INVENTION

It is an object of this invention to provide chimeric macromolecules that hybridize with a target strand with improved binding affinity.

It is a further object to provide chimeric macromolecules that have stability against nuclease degradation.

A still further object is to provide chimeric macromolecules that activate RNase H for target strand cleavage.

A still further object is to provide research and diagnostic methods and materials for assaying cellular states in vitro and bodily states, especially diseased states, in animals.

Another object is to provide therapeutic and research methods and materials for the treatment of diseases through modulation of the activity of a target RNA.



## BRIEF DESCRIPTION OF THE INVENTION

In accordance with this invention there are provided macromolecules formed from peptide nucleic acids and 2'-deoxy-oligonucleotides. Such macromolecules have the structure: PNA-DNA-PNA, wherein the PNA portions are peptide nucleic acid sequences and the DNA portion is a phosphodiester, phosphorothioate or phosphorodithioate 2'-deoxyoligonucleotide sequence. The PNA portions of the macromolecule is believed to provide increased nuclease resistance and increased binding affinity of the macromolecule to target RNAs. The 2'-deoxyoligonucleotide portion is believed to elicit a RNase H response and cleavage of a RNA target strand.

The 2'-deoxyoligonucleotide, i.e. DNA, portions of the macromolecules of the invention are oligonucleotide segments formed from nucleotide units that have 2'-deoxy-erythro-pentofuranosyl sugar moieties. Each nucleotide includes a nucleobase attached to a 2'-deoxy-erythro-pentofuranosyl sugar moiety of the nucleotide. The nucleotides are linked together and/or to other moieties by phosphodiester linkages, phosphorothioate linkages and/or phosphorodithioate linkages. In certain preferred macromolecules of the invention each of the nucleotides of the 2'-deoxyoligonucleotide portion of the macromolecule are linked together by phosphorothioate linkages. In other preferred embodiments, the nucleotides of the 2'-deoxyoligonucleotide portion are linked together by phosphodiester linkages and in even further preferred embodiments, a mixture of phosphodiester and phosphorothioate linkages link the nucleotide units of the 2'-deoxyoligonucleotide together.

The peptide nucleic acid portions of the macromolecules increase the binding affinity of the macromolecule to a complementary strand of nucleic acid. It further provides for nuclease stability of the macromolecule against degradation by cellular nucleases. Selecting the 2'-deoxyoligonucleotide portion of the macromolecule to include one or more or all phosphorothioate or phosphorodithioate linkages provides

further nuclease stability to the macromolecules of the invention.

The PNA portions of the macromolecules of the invention are made up of units comprising a N-(2-aminoethyl)-glycine or analogues thereof having a nucleobase attached thereto via a linker such as a carboxymethyl moiety or analogues thereof to the nitrogen atom of the glycine portion of the unit. The units are coupled together via amide bonds formed between the carboxyl group of the glycine moiety and the amine group of the aminoethyl moiety. The nucleobase can be one of the four common nucleobases of nucleic acids or they can include other natural or synthetic nucleobases.

In preferred macromolecules of the invention the PNA-DNA-PNA structure is formed by connecting together the respective N-(2-aminoethyl)glycine PNA units and the respective 2'-deoxy-erythro-pentofuranosyl sugar phosphate DNA units. Thus the nucleobases of the PNA portion of the macromolecules of the invention are carried on a backbone composed of N-(2-aminoethyl)glycine PNA units and the nucleobases of the DNA portion of the macromolecules of the invention are carried on a backbone composed of 2'-deoxy-erythro-pentofuranosyl sugar phosphate units. Together the nucleobases of the PNA portions and the nucleobases of the DNA portion of the macromolecules of the invention are connected by their respective backbone units in a sequence that is hybridizable to a complementary nucleic acid, as for instance, a targeted RNA stand.

In preferred macromolecules of the invention the PNA and the DNA portions are joined together with amide linkages. In such preferred macromolecule of the invention the macromolecule is of the structure:

PNA-(amide link)-DNA-(amide link)-PNA.

Other linkages that can be used to join the PNA and the DNA portions include amine linkages and ester linkages.

The macromolecules of the invention preferably comprise from about 9 to about 30 total nucleobase bearing subunits. It is more preferred that the macromolecules comprise from about 15 to about 25 nucleobase bearing subunits.

In order to elicit a RNase H response, as specified above, within this total overall sequence length of the macromolecule will be a sub-sequence of greater than 3 but preferably five or more consecutive 2'-deoxy-erythro-pentofuranosyl containing 5 nucleotide subunits.

Preferred nucleobases of the invention for both the peptide nucleic acid and the 2'-deoxynucleotide subunits include adenine, guanine, cytosine, uracil, thymine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl  
10 adenines, 2-propyl and other alkyl adenines, 5-halo uracil, 5-halo cytosine, 5-propynyl uracil, 5-propynyl cytosine, 7-deazaadenine, 7-deazaguanine, 7-deaza-7-methyl-adenine, 7-deaza-7-methyl-guanine, 7-deaza-7-propynyl-adenine, 7-deaza-7-propynyl-guanine and other 7-deaza-7-alkyl or 7-aryl purines,  
15 N2-alkyl-guanine, N2-alkyl-2-amino-adenine, purine 6-aza uracil, 6-aza cytosine and 6-aza thymine, 5-uracil (pseudo uracil), 4-thiouracil, 8-halo adenine, 8-amino-adenine, 8-thiol adenine, 8-thiolalkyl adenines, 8-hydroxyl adenine and other 8 substituted adenines and 8-halo guanines, 8-amino guanine, 8-  
20 thiol guanine, 8-thiolalkyl guanines, 8-hydroxyl guanine and other 8 substituted guanines, other aza and deaza uracils, other aza and deaza thymidines, other aza and deaza cytosine, aza and deaza adenines, aza and deaza guanines or 5-trifluoromethyl uracil and 5-trifluorocytosine.

25 The invention also provides methods of treating an organism having a disease characterized by the undesired production of a protein. These methods include contacting the organism with a macromolecule having a sequence of nucleobases capable of specifically hybridizing to a complementary strand  
30 of nucleic acid. The methods further including having a portion of the nucleobases comprise peptide nucleic acid subunits (PNA units) and the remainder of the nucleobases comprise 2'-deoxynucleotide subunits (DNA units). The peptide nucleic acid subunits and the deoxynucleotide subunits are  
35 joined together to form a macromolecule of the structure PNA-DNA-PNA where the PNAs are peptide nucleic acids and DNA is an 2'-deoxyoligonucleotide.

Further in accordance with this invention there are provided compositions including a pharmaceutically effective amount of a macromolecule having a sequence of nucleobases capable of specifically hybridizing to a complementary strand  
5 of nucleic acid. The methods further include having a portion of the nucleobases comprise peptide nucleic acid subunits (PNA units) and the remainder of the nucleobases comprise 2'-deoxy-nucleotide subunits (DNA units). The peptide nucleic acid subunits (the PNAs) and the deoxynucleotides subunits (the DNA)  
10 are joined together to form a macromolecule of the structure PNA-DNA-PNA. The composition further include a pharmaceutically acceptable diluent or carrier.

Further in accordance with this invention there are provided methods for *in vitro* modification of a sequence  
15 specific nucleic acid including contacting a test solution containing an RNase H enzyme and said nucleic acid with a PNA-DNA-PNA macromolecule, as defined above.

There are also provided methods of concurrently enhancing hybridization and RNase H enzyme activation in an  
20 organism that includes contacting the organism with a PNA-DNA-PNA macromolecule, as defined above.

#### BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a chemical schematic illustrating solid phase synthesis of certain compounds of the invention;  
25

Figure 2 is a chemical schematic illustrating solid phase synthesis of certain compounds of the invention;

Figure 3 is a chemical schematic illustrating solution phase synthesis of certain compounds of the invention;

Figure 4 is a chemical schematic illustrating solution  
30 phase synthesis of certain compounds of the invention;

Figure 5 is a chemical schematic illustrating solid phase synthesis of certain compounds of the invention; and

Figure 6 is a chemical schematic illustrating solution phase synthesis of certain compounds of the invention.

## DETAILED DESCRIPTION OF THE INVENTION

In accordance with the objects of this invention, novel macromolecules are provided that, at once, have increased nuclease resistance, increased binding affinity to complementary strands and that are substrates for RNase H. The macromolecules of the invention are assembled from a plurality of peptide nucleic acid subunits (PNA subunits) and a plurality of 2'-deoxynucleotide subunits (DNA subunits). They are assembled into a macromolecule of the structure: PNA-DNA-PNA. Each peptide nucleic acid subunit and each 2'-deoxynucleotide subunit includes a nucleobase that is capable of specifically hybridizing with like nucleobases on a target RNA molecules or other target molecules including DNA molecules and proteins.

The peptide nucleic acid portions of the macromolecules of the invention bestow increased nuclease resistance to the macromolecules of the invention. Further, these same peptide nucleic acid portions bestow increased binding affinity of the macromolecules of the invention to a complementary strand of nucleic acid. The 2'-deoxynucleotide portion of the macromolecules of the invention each include a 2'-deoxy-erythro-pentofuranosyl group as their sugar moiety.

In conjunction with the above guidelines, each of the 2'-deoxynucleotide subunits can be a "natural" or a "synthetic" moiety. Thus, in the context of this invention, the term "oligonucleotide" in a first instance refers to a polynucleotide formed from a plurality of joined nucleotide units. The nucleotides units are joined together via native internucleoside, phosphodiester linkages. The nucleotide units are formed from naturally-occurring bases and 2'-deoxy-erythro-pentofuranosyl sugars groups. The term "oligonucleotide" thus effectively includes naturally occurring species or synthetic species formed from naturally occurring nucleotide units.

The term oligonucleotide is intended to include naturally occurring structures as well as non-naturally occurring or "modified" structures -- including modified base moieties that function similarly to natural bases. The nucleotides of the 2'-deoxyoligonucleotide portion of the

macromolecule can be joined together with other selected synthetic linkages in addition to the natural phosphodiester linkage. These other linkages include phosphorothioate and phosphorodithioate inter-sugar linkages. Further suggested as  
5 suitable linkages are phosphoroselenate and phosphorodiselenate linkages. The base portion, i.e., the nucleobase of the 2'-deoxynucleotides, can include the natural bases, i.e. adenine, guanine, cytosine, uracil or thymidine. Alternately they can include deaza or aza purines and pyrimidines used in place of  
10 natural purine and pyrimidine bases; pyrimidine bases having substituent groups at the 5 or 6 position; purine bases having altered or replacement substituent groups at the 2, 6 or 8 positions. They may also comprise other modifications consistent with the spirit of this invention. Such 2'-deoxyoligo-  
15 nucleotides are best described as being functionally interchangeable with natural oligonucleotides (or synthesized oligonucleotides along natural lines), but which have one or more differences from natural structure. All such 2'-deoxyoligonucleotides are comprehended by this invention so long as  
20 they function effectively in the macromolecule to elicit the RNase H cleavage of a target RNA strand.

In one preferred embodiment of this invention, nuclease resistance beyond that confirmed by the peptide nucleic acid portion of the macromolecule is achieved by  
25 utilizing phosphorothioate internucleoside linkages. Contrary to the reports of Walder, et al. note above, I have found that in systems such as fetal calf serum containing a variety of 3'-exonucleases, modification of the internucleoside linkage from a phosphodiester linkage to a phosphorothioate linkage provides  
30 nuclease resistance.

Brill, et al., *J. Am. Chem. Soc.* **1991**, *113*, 3972, recently reported that phosphorodithioate oligonucleotides also exhibit nuclease resistance. These authors also reported that phosphorodithioate oligonucleotide bind with complementary  
35 deoxyoligonucleotides, stimulate RNase H and stimulate the binding of *lac* repressor and *cro* repressor. In view of these properties, phosphorodithioates linkages also may be use in the

2'-deoxyoligonucleotide portion of the macromolecules of the invention. The synthesis of phosphorodithioates is further described by Beaton, et. al., Chapter 5, Synthesis of oligonucleotide phosphorodithioates, page 109, *Oligonucleotides and Analogs, A Practical Approach*, Eckstein, F., Ed.; The Practical Approach Series, IRL Press, New York, 1991.

When increased nuclease resistance is conferred upon a macromolecule of the invention by the use of a phosphorothioate or phosphorodithioates internucleotide linkages, such linkages will reside in each internucleotide sites. In other embodiments, less than all of the internucleotide linkages will be modified to phosphorothioate or phosphorodithioate linkages.

I have found that binding affinity of macromolecules of the invention is increased by virtue of the peptide nucleic acid portions of the macromolecules. As for example the  $T_m$  of a 10 mer homothymidine PNA binding to its complementary 10 mer homoadenosine DNA is 73 °C whereas the  $T_m$  for the corresponding 10 mer homothymidine DNA to the same complementary 10 homoadenosine DNA is only 23 °C.

Binding affinity also can be increased by the use of certain modified bases in both the nucleotide subunits that make up the 2'-deoxyoligonucleotides of the invention and in the peptide nucleic acid subunits. Such modified bases may include 5-propynylpyrimidines, 6-azapyrimidines, and N-2, N-6 and O-6 substituted purines including 2-aminopropyladenine. Other modified pyrimidine and purine base are also expected to increase the binding affinity of macromolecules to a complementary strand of nucleic acid.

For use in preparing such structural units, suitable nucleobases include adenine, guanine, cytosine, uracil, thymine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 5-halo uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudo uracil), 4-thiouracil, 8-halo, amino, thiol, thiol-alkyl, hydroxyl and other 8 substituted adenines and guanines, 5-trifluoromethyl and other 5 substituted uracils and

cytosines, 7-methylguanine and other nucleobase such as those disclosed in United States Patent Number 3,687,808, those disclosed in the *Concise Encyclopedia Of Polymer Science And Engineering*, J.I. Kroschwitz, Ed. John Wiley & Sons, 1990 at 5 pages 858-859 and those disclosed by Englisch, U. and Gauss, D.H., *Angewandte Chemie, International Edition* 1991, 30, 613 are selected.

In order to elicit RNase H enzyme cleavage of a target RNA, a macromolecule of the invention must include a segment or 10 sub-sequence therein that is a DNA type segment. Stated otherwise, at least a portion of the macromolecules of the invention must be nucleotide subunits having 2'-deoxy-erythro-pentofuranosyl sugar moieties. I have found that a sub-sequence having more than three consecutive, linked 2'-deoxy-erythro-pentofu- 15 ranosyl-containing nucleotide subunits likely is necessary in order to elicit RNase H activity upon hybridization of a macromolecule of the invention with a target RNA. It is presently preferred to have a sub-sequence of 5 or more consecutive 2'-deoxy-erythro-pentofuranosyl containing nucleotide subunits in 20 a macromolecule of the invention. Use of at least 7 consecutive 2'-deoxy-erythro-pentofuranosyl-containing nucleotide subunits is particularly preferred.

The overall length of the macromolecules of the invention can be from 3 to hundreds of subunits long; however, since 25 target specificity can be achieved with a much shorter molecule, a more practical maximum length will be from about 30 to about 50 subunits long. An even more preferred maximum length will be about 25 subunits long.

Depending upon the target, the minimum length of the 30 macromolecule will vary from three to about fifteen total subunits. It has been found in practice that in using anti-sense oligonucleotides generally a minimum length of about 15 nucleotides is necessary to insure proper affinity upon hybridization. However as noted above, since the peptide nucleic 35 acid subunits have a greater hybridization affinity for target molecules compared to normal phosphodiester oligonucleotides that in turn have a better affinity than phosphorothioate



oligonucleotides, in using the macromolecules of the invention, a minimum length less than that normally use in practicing antisense binding with antisense oligonucleotides can be expected. Taking these factors in to consideration a preferred  
5 length of the macromolecules will be from about 3 to about 30 total subunits with a more preferred range from about 9 to about 25 subunits in length.

In the macromolecules of the invention, there will be one or more sequential DNA units interspaced between PNA units.  
10 To elicit a RNase H response, as noted above preferably the DNA portion of the macromolecule will have at least three 2'-deoxy-nucleotide units. In determining an upper range of the number of DNA units, consideration is given to several factors including overall length of the macromolecule, the phosphate  
15 linkage utilized, desired fidelity to a target sequence and other like factors. Normally, for economic considerations it is desirable not to have more nucleobase units in the macromolecules of the invention than is necessary to bind with specificity to a target molecule and, if desired, to elicit an  
20 RNase H response. For utilization of the RNase H mechanism this number is generally about 5 nucleotides. Additionally since phosphorothioate and phosphorodithioate phosphate linkage themselves exhibit nuclease resistance, with use of these two phosphate linkages, a longer stretch of DNA subunits can be  
25 utilized compared to phosphodiester subunits that must rely on the PNA portions of the macromolecule for nuclease resistance. Taking these factors into account, a particularly preferred working range includes macromolecules of the invention is from 9 to about 28 subunits in length and having from about five to  
30 about eight of those subunits being sequential located 2'-deoxynucleotide subunits.

The mechanism of action of RNase H is recognition of a DNA-RNA duplex followed by cleavage of the RNA stand of this duplex. As noted in the Background section above, others in  
35 the art have used modified DNA strands to impart nuclease stability to the DNA strand. To do this they have used modified phosphate linkages that impart increased nuclease

stability but concurrently detract from hybridization properties.

While I do not wish to be bound by theory in the macromolecules of the invention, I have recognized that by  
5 positioning peptide nucleic acid units at both ends of a 2'-deoxyoligonucleotide portion of the macromolecule this will impart nuclease stability to the macromolecule. Further this will also impart increase binding and specificity to a complementary strand.

10 Again, while not wishing to be bound by any particular theory, I have recognized certain criteria that must be met for RNase H to recognize and elicit cleavage of a RNA strand. The first of these is that the RNA stand at the cleavage site must have its nucleosides connected via a phosphate linkage that  
15 bears a negative charge. Additionally, the sugar of the nucleosides at the cleavage site must be a  $\beta$ -pentofuranosyl sugar and also must be in a 2' endo conformation. The only nucleosides (nucleotides) that fit this criteria are phosphodiester, phosphorothioate, phosphorodithioate, phosphoroselenate and  
20 phosphorodiselenate nucleotides of 2'-deoxy-erythro-pentofuranosyl  $\beta$ -nucleosides.

In view of the above criteria, even certain nucleosides that have been shown to reside in a 2' endo conformation (e.g., cyclopentyl nucleosides) will not elicit RNase H  
25 activity since they do not incorporate a pentofuranosyl sugar. Modeling has shown that oligonucleotide 4'-thionucleosides also will not elicit RNase H activity, even though such nucleosides reside in an envelope conformation, since they do not reside in a 2' endo conformation. Additionally, since  $\alpha$ -nucleosides are  
30 of the opposite configuration from  $\beta$ -pentofuranosyl sugars they also will not elicit RNase H activity.


Nucleobases that are attached to phosphate linkages via non-sugar tethering groups or via non-phosphate linkages also do not meet the criteria of having a  $\beta$ -pentofuranosyl  
35 sugar in a 2' endo conformation. Thus, they likely will not elicit RNase H activity.

0337737 "03409"

For incorporation into the 2'-deoxyoligonucleotide portion of the macromolecule of the invention, nucleosides will be blocked in the 5' position with a dimethoxytrityl group, followed by phosphitylation in the 3' position as per the trit-  
5 ylation and phosphitylation procedures reported in *Oligonucleotides and Analogs, A Practical Approach*, Eckstein, F., Ed.; The Practical Approach Series, IRL Press, New York, 1991. Incorporation into oligonucleotides will be accomplished utilizing a DNA synthesizer such as an ABI 380 B model synthesizer using  
10 appropriate chemistry for the formation of phosphodiester, phosphorothioate or phosphorodithioate phosphate linkages as per the synthetic protocols illustrated in Eckstein op. cit.

The 2'-deoxynucleotide subunits and the peptide nucleic acid subunits of the macromolecules of the invention  
15 are joined by covalent bonds to fix the subunits of the macromolecule in the desired nucleobase sequence. A covalent interconnection of a desired length is formed between each of the two adjacent regions of the macromolecule. Preferably a covalent interconnection is achieved by selecting a linking moiety  
20 that can form a covalent bond to both of the different types of subunit moieties forming the adjacent regions. Preferably the linking moiety is selected such that the resulting chain of atoms between the linking moiety and the different types of moieties is of the same length. In one preferred embodiment of  
25 the invention, particularly useful as a linkage that interconnect the 2'-deoxynucleotide and peptide nucleic acid subunits are amide linkages. In other embodiments amine and ester linkages can be used.

The peptide nucleic acid subunit portions (the PNA  
30 portions) of the macromolecules of the invention have the general formula (I):



(I)

wherein:

n is at least 2,

each of  $L^1-L^n$  is independently selected from the group consisting of hydrogen, hydroxy,  $(C_1-C_4)$ alkanoyl, naturally occurring nucleobases, non-naturally occurring nucleobases, aromatic moieties, DNA intercalators, nucleobase-binding groups, heterocyclic moieties, and reporter ligands, at least one of  $L^1-L^n$  being a naturally occurring nucleobase, a non-naturally occurring nucleobase, a DNA intercalator, or a nucleobase-binding group;

each of  $C^1-C^n$  is  $(CR^6R^7)_y$ , where  $R^6$  is hydrogen and  $R^7$  is selected from the group consisting of the side chains of naturally occurring alpha amino acids, or  $R^6$  and  $R^7$  are independently selected from the group consisting of hydrogen,  $(C_2-C_6)$ alkyl, aryl, aralkyl, heteroaryl, hydroxy,  $(C_1-C_6)$ alkoxy,  $(C_1-C_6)$ alkylthio,  $NR^3R^4$  and  $SR^5$ , where  $R^3$  and  $R^4$  are as defined above, and  $R^5$  is hydrogen,  $(C_1-C_6)$ alkyl, hydroxy-, alkoxy-, or alkylthio- substituted  $(C_1-C_6)$ alkyl, or  $R^6$  and  $R^7$  taken together complete an alicyclic or heterocyclic system;

each of  $D^1-D^n$  is  $(CR^6R^7)_z$ , where  $R^6$  and  $R^7$  are as defined above;


each of y and z is zero or an integer from 1 to 10, the sum  $y + z$  being greater than 2 but not more than 10;

each of  $G^1-G^{n-1}$  is  $-NR^3CO-$ ,  $-NR^3CS-$ ,  $-NR^3SO-$  or  $-NR^3SO_2-$ , in either orientation, where  $R^3$  is as defined above;


each pair of  $A^1-A^n$  and  $B^1-B^n$  are selected such that:

(a) A is a group of formula (IIa), (IIb) or (IIc) and B is N or  $R^3N^+$ ; or


(b) A is a group of formula (IIId) and B is CH;




(IIa)



(IIb)



(IIc)



(IId)

where:

5

X is O, S, Se, NR<sup>3</sup>, CH<sub>2</sub> or C(CH<sub>3</sub>)<sub>2</sub>;

Y is a single bond, O, S or NR<sup>4</sup>;

each of p and q is zero or an integer from 1 to 5, the sum p+q being not more than 10;

10

each of r and s is zero or an integer from 1 to 5, the sum r+s being not more than 10;

each R<sup>1</sup> and R<sup>2</sup> is independently selected from the group consisting of hydrogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl which may be hydroxy- or alkoxy- or alkylthio-substituted, hydroxy, alkoxy, alkylthio, amino and halogen;


15

each of G<sup>1</sup>-G<sup>n-1</sup> is -NR<sup>3</sup>CO-, -NR<sup>3</sup>CS-, -NR<sup>3</sup>SO- or -NR<sup>3</sup>SO<sub>2</sub>-, in either orientation, where R<sup>3</sup> is as defined above;


Q is -CO<sub>2</sub>H, -CONR'R'', -SO<sub>3</sub>H or -SO<sub>2</sub>NR'R'' or an activated derivative of -CO<sub>2</sub>H or -SO<sub>3</sub>H; and

I is -NHR'''R'''' or -NR'''C(O)R''''', where R', R'', R''' and R'''' are independently selected from the group consisting of hydrogen, alkyl, amino protecting groups, reporter ligands, intercalators, chelators, peptides, proteins, carbohydrates, lipids, steroids, nucleosides, nucleotides, nucleotide diphosphates, nucleotide triphosphates, oligonucleo-  
25 tides, oligonucleosides and soluble and non-soluble polymers.


(IIIa) - (IIIc) :



(IIIa)



(IIIB)



(IIIC)

5

wherein:

each L is independently selected from the group consisting of hydrogen, phenyl, heterocyclic moieties,

naturally occurring nucleobases, and non-naturally occurring nucleobases;

each R<sup>7'</sup> is independently selected from the group consisting of hydrogen and the side chains of naturally occurring alpha amino acids;

n is an integer from 1 to 60;

each of k, l, and m is independently zero or an integer from 1 to 5;

p is zero or 1;

R<sup>h</sup> is OH, NH<sub>2</sub> or -NHLysNH<sub>2</sub>; and


R<sup>i</sup> is H or COCH<sub>3</sub>.

Particularly preferred are compounds having formula (IIIa)-(IIIc) wherein each L is independently selected from the group consisting of the nucleobases thymine (T), adenine (A), cytosine (C), guanine (G) and uracil (U), k and m are zero or 1, and n is an integer from 1 to 30, in particular from 4 to 20.

The peptide nucleic acid portions of the macromolecules of the invention are synthesized by procedures, either in solution or on a solid phase, generally following the procedures described in patent application PCT/EP/01219 that published on November 26, 1992 as publication WO 92/20702 or United States patent application 08/088,658, filed July 2, 1993 or by equivalent procedures. The contents of these patent applications are herein incorporated by reference.


The synthons used are monomer amino acids or their activated derivatives, protected by standard protecting groups. The PNAs also can be synthesized by using the corresponding diacids and diamines.

The novel monomer synthons according to the invention are selected from the group consisting of amino acids, diacids and diamines having general formulae:




wherein L, A, B, C and D are as defined above, except that any amino groups therein may be protected by amino protecting groups; E is COOH, CSOH, SOOH, SO<sub>2</sub>OH or an activated derivative thereof; and F is NHR<sup>3</sup> or NPgR<sup>3</sup>, where R<sup>3</sup> is as defined above  
 5 and Pg is an amino protecting group.

Preferred monomer synthons according to the invention have formula (VIIIa)-(VIIIc):




(VIIIa)



(VIIIb)





(VIIIC)

or amino-protected and/or acid terminal activated derivatives thereof, wherein L is selected from the group consisting of hydrogen, phenyl, heterocyclic moieties, naturally occurring  
5 nucleobases, and non-naturally occurring nucleobases; and R'' is selected from the group consisting of hydrogen and the side chains of naturally occurring alpha amino acids.

Compounds of the invention can be utilized in diagnostics, therapeutics and as research reagents and kits. Further once identified as being active in a test system, they can be used as standards in testing systems for other active compounds including chemotherapeutic agents. They can be utilized in pharmaceutical compositions by including an effective amount of a macromolecule of the invention admixed with a suitable pharmaceutically acceptable diluent or carrier. They further can be used for treating organisms having a disease characterized by the undesired production of a protein. The organism can be contacted with a macromolecule of the invention having a sequence that is capable of specifically hybridizing with a strand of nucleic acid that codes for the undesirable protein.

Such therapeutic treatment can be practiced in a variety of organisms ranging from unicellular prokaryotic and eukaryotic organisms to multicellular eukaryotic organisms.

25 Any organism that utilizes DNA-RNA transcription or RNA-protein translation as a fundamental part of its hereditary, metabolic or cellular control is susceptible to such therapeutic and/or

prophylactic treatment. Seemingly diverse organisms such as bacteria, yeast, protozoa, algae, all plant and all higher animal forms, including warm-blooded animals, can be treated by this therapy. Further, since each of the cells of multi-  
5 cellular eukaryotes also includes both DNA-RNA transcription and RNA-protein translation as an integral part of their cellular activity, such therapeutics and/or diagnostics can also be practiced on such cellular populations. Furthermore, many of the organelles, e.g., mitochondria and chloroplasts, of  
10 eukaryotic cells also include transcription and translation mechanisms. As such, single cells, cellular populations or organelles also can be included within the definition of organisms that are capable of being treated with the therapeutic or diagnostic oligonucleotides of the invention. As  
15 used herein, therapeutics is meant to include both the eradication of a disease state, killing of an organism, e.g., bacterial, protozoan or other infection, or control of erratic or harmful cellular growth or expression.

For purpose of illustration, the compounds of the  
20 invention are used in a ras-luciferase fusion system using ras-luciferase transactivation. As described in United States Patent Application Serial Number 07/715,196, filed June 14, 1991, entitled Antisense Inhibition of RAS Oncogene and assigned commonly with this application, the entire contents of  
25 which are herein incorporated by reference, the ras oncogenes are members of a gene family that encode related proteins that are localized to the inner face of the plasma membrane. Ras proteins have been shown to be highly conserved at the amino acid level, to bind GTP with high affinity and specificity, and  
30 to possess GTPase activity. Although the cellular function of ras gene products is unknown, their biochemical properties, along with their significant sequence homology with a class of signal-transducing proteins known as GTP binding proteins, or G proteins, suggest that ras gene products play a fundamental  
35 role in basic cellular regulatory functions relating to the transduction of extracellular signals across plasma membranes.

Three ras genes, designated H-ras, K-ras, and N-ras, have been identified in the mammalian genome. Mammalian ras genes acquire transformation-inducing properties by single point mutations within their coding sequences. Mutations in naturally occurring ras oncogenes have been localized to codons 12, 13, and 61. The sequences of H-ras, K-ras and N-ras are known. Capon et al., *Nature* 302 1983, 33-37; Kahn et al., *Anticancer Res.* 1987, 7, 639-652; Hall and Brown, *Nucleic Acids Res.* 1985, 13, 5255-5268. The most commonly detected activating ras mutation found in human tumors is in codon 12 of the H-ras gene in which a base change from GGC to GTC results in a glycine-to-valine substitution in the GTPase regulatory domain of the ras protein product. Tabin, C.J. et al., *Nature* 1982, 300, 143-149; Reddy, P.E. et al., *Nature* 1982, 300, 149-152; Taparowsky, E. et al., *Nature* 1982, 300, 762-765. This single amino acid change is thought to abolish normal control of ras protein function, thereby converting a normally regulated cell protein to one that is continuously active. It is believed that such deregulation of normal ras protein function is responsible for the transformation from normal to malignant growth. Monia, et. al., *J. Bio. Chem.*, 1993, 268, 14514-14522, have recently shown, via a transactivation reporter gene system, that chimeric "Gap" (structure having a 2'-deoxyoligonucleotide flanked by non-deoxyoligonucleotides) are active in vitro against the Ha-ras oncogene. Compounds of the invention active in the above described assays can be used as standards in in vitro chemotherapeutic agent test screens.

Compounds of the invention can be prepared via both solid phase synthesis or solution phase synthesis. Both methods are illustrated in the examples. Shown in the examples, in Example 1 is a general synthetic preparation of the 2'-deoxyoligonucleotide portion of the macromolecules of the invention. The schemes of Examples 2, 3 and 4 are illustrated in Figure 1. Example 2 illustrates describes loading of the carboxy terminus of the right side PNA portion of the macromolecule to a solid support resin. Example 3 describes elongation of this right side PNA portion of the

macromolecule and formation of an amide linkage to a first 2'-deoxynucleotide via a 3'-carboxy nucleoside. Example 4 illustrates the elongation of the central 2'-deoxyoligonucleotide portion of the macromolecule including addition of 5'-aminonucleotide to effect an amide linkage to the second PNA (left side) portion of the macromolecule. The schemes of Examples 5 and 6 are shown in Figure 2. Example 5 shows completion of the left side PNA portion. Example 6 illustrated removal of the blocking groups and removal from the resin. The scheme of Example 7 is shown in Figure 3. Example 7 illustrates the formation of a solution phase DNA linkages for positioning of a 5'-amino-3'-nucleotide as the 5'-terminal nucleotide. The schemes of Examples 8 and 9 are shown in Figures 4 and 5, respective. Example 8 illustrates solution phase the solution phase coupling of a PNA portion of a macromolecule of the invention to the DNA portion. In this example, the oligonucleotide of Example 7 is coupled to a first "T" PNA subunit; whereas, in Example 9 a first "A" PNA subunit is coupled to the 2'-deoxyoligonucleotide portion of the macromolecule. The schemes of Examples 10, 11 and 12 are shown in Figure 6. Example 10, 11 and 12 are illustrative of the solution phase coupling of a DNA portion of a macromolecule of the invention to a PNA portion.

In the below examples the subunits, irrespective of whether they are peptide nucleic acid (PNA) groups or 2'-deoxynucleotides (DNA) groups, the subunits are identified using the standard capital one letter designations, i.e. A, G, C or T. Such designation is indicative of the nucleobase incorporated in to the subunits. Thus "A" is used both to identify a 2'-deoxyadenosine nucleotide as well as a peptide nucleic acid subunit that include an adenine base. For the peptide nucleic acid subunit the adenine base is attached to the N-(2-aminoethyl)glycine backbone via carboxymethyl linker. A standard nucleotide linkage, i.e., phosphodiester, phosphorothioate, phosphorodithioate or phosphoroselenate, is indicated by a hyphen ( - ) between two adjacent identification letters, e.g. A-T indicates an adenosine nucleotide linked to a thymi-

dine nucleotide. To indicate a peptide nucleic acid linkage either a "(p)" or a "(pna)" are utilized, e.g. A(p)-T indicates an adenine peptide nucleic acid unit attached to a thymine peptide nucleic acid unit.

5 Transition linkages between 2'-deoxynucleotides and peptide nucleic acid units are indicated in brackets. Thus " T-(3'-carboxy)-A " indicated a thymidine nucleoside having a carboxy group at its 3' position that is linked to the amine moiety of the 2-aminoethyl portion of adenine peptide nucleic  
10 acid subunit. Whereas " A-(5'-amino)-T " would indicate a thymidine nucleotide having an amine at its 5' position that is linked to the carboxyl moiety of the glycine portion of the adjacent thymine peptide nucleic acid subunit. Terminal groups, e.g. carboxy, hydroxyl, N-acetylglycine and the like,  
15 are indicated using appropriate symbolic nomenclature.

Carbobenzoxy blocking groups are shown as a superscript Z, e.g., <sup>Z</sup>. Phenoxyacetyl protecting group are shown as a superscript PAC, e.g., <sup>PAC</sup>. As alternatives for the standard polystyrene Merrifield resin described, a highly cross-linked  
20 polystyrene sold by Pharmacia or a polyethyleneglycol/polystyrene graft copolymer called Tentagel sold by Rapp Polymere might be used. To conveniently remove the macromolecules of the invention, the glycine should be attached to the resin via an ester linkage.

25 The following examples and procedures illustrate the present invention and are not intended to limit the same.

#### EXAMPLE 1

##### Oligonucleotide synthesis:

Oligonucleotide portions of the macromolecules of the  
30 invention are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidate chemistry with oxidation by iodine. For phosphorothioate oligonucleotides, the standard oxidation bottle is replaced by 0.2 M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in  
35 acetonitrile for the step wise thiation of the phosphite linkages. The thiation wait step was increased to 68 sec and

was followed by the capping step. Unless otherwise indicated, after cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55 °C (18 hr), the oligonucleotides are purified by precipitation twice out of 0.5 M NaCl solution with 2.5 volumes ethanol. Analytical gel electrophoresis is effected in 20% acrylamide, 8 M urea, 454 mM Tris-borate buffer, pH=7.0. Phosphodiester and phosphorothioate oligonucleotides are judged from polyacrylamide gel electrophoresis as to material length.

## 10 EXAMPLE 2

### Low Load t-butyloxycarbonylglycyl Merrifield resin

Hydroxymethyl polystyrene resin (1g, 650 micromoles hydroxyl/g) was placed in a solid-phase peptide synthesis vessel and washed sequentially (1 minute shaking for each wash) with dichloromethane (DCM, 2 times 10 mL), N,N-dimethylformamide (DMF, 2 times 10 mL), and acetonitrile (2 times 40 mL). To a round-bottom flask was added N-t-butyloxycarbonylglycine (701 mg, 4 mmoles) and O-(benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (1.156 g, 3.6 mmoles). Anhydrous acetonitrile (40 mL) was added to the vial followed by N,N-diisopropylethylamine (1.392 mL, 8 mmoles). The flask was shaken until all solids were dissolved. After one minute the contents of the vial were added to the peptide synthesis vessel and shaken for 125 minutes. The reaction solution was then drained away and the support washed with acetonitrile (1 times 40 mL), pyridine (2 times 40 mL) and DMF (2 times 40 mL). A solution of 10% (v/v) acetic anhydride in DMF (40 mL total volume) was added to the resin and the reaction shaken for 40 minutes. After draining off the reaction solution, the acetic anhydride cap was repeated as above. At the end of the second capping reaction the resin was washed with DMF (2 times 40 mL), pyridine (1 times 40 mL), and DCM (3 times 40 mL). The resin was then dried by blowing with argon.

The extent of glycine derivatization was determined by a quantitative ninhydrin assay. An aliquot of the above resin (50 mg) was placed in a solid-phase peptide synthesis

vessel and washed with DCM (2 times 3 mL). The resin was then treated three times with a solution of 5% (v/v) *m*-cresol in trifluoroacetic acid (3 mL) with shaking for two minutes each time. After draining off the third reaction solution, the  
5 resin was washed with DCM (3 times 3 mL), pyridine (3 times 3 mL), and DCM (3 times 3 mL). The resin was then dried by blowing with argon.

An aliquot (5 mg) of the deprotected dried resin was placed in a test tube. To the resin were added a solution of  
10 70% (v/v) water/pyridine (80 microL), Kaiser reagent 1 (100 microL, 200 micromolar KCN in 2% H<sub>2</sub>O/pyridine), reagent 2 (40 microL, 5% [w/v] ninhydrin in *n*-BuOH), and reagent 3 (50 micro-liters, 80% [w/v] phenol in *n*-BuOH). The reaction was heated at 100 °C for 10 minutes, cooled and diluted with 60% (v/v)  
15 EtOH (7 mL). The absorbance at 570 nm was then compared to a control reaction containing no resin and to a standard curve based on quantitation of glycine ethyl ester. A derivatization level of 100 micromoles glycine per gram resin was obtained.

### 20 EXAMPLE 3

#### 5'-Hydroxy-T(3'-carboxy)-T(p)-C<sup>z</sup>(p)-A<sup>z</sup>(p)-G<sup>z</sup>(p)-Gly-O-Resin

*t*-Butyloxycarbonylglycyl Merrifield resin (200 mg, 10 microequivalents, example 1) is placed in a solid-phase peptide synthesis vessel. The support is washed with 50% DMF/DCM (4  
25 times 5 mL) and then treated twice with 5% *m*-cresol in trifluoroacetic acid (4 mL) with shaking for two minutes each time. The support is washed again with 50% DMF/DCM (4 times 5 mL) and then with pyridine (5 times 5 mL). To a vial are added N<sup>2</sup>-benzyloxycarbonyl-1-(*t*-butyloxycarbonyl-aminoethylglycyl)gua  
30 nine (80 micromoles) and O-(benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (72 micromoles). *N,N*-Dimethylformamide (0.4 mL) and pyridine (0.4 mL) are added to the vial followed by *N,N*-diisopropylethylamine (160 micromoles). The vial is shaken until all solids are dissolved. After one  
35 minute the contents of the vial are added to the peptide synthesis vessel and shaken for 20 minutes. The reaction solution is then drained away and the support washed with

pyridine (4 times 5 mL). Remaining free amine is capped by addition of a 10% solution of N-benzyloxycarbonyl-N'-methylimidazole triflate in N,N-dimethylformamide (0.8 mL). After shaking for five minutes, the capping solution is drained and  
5 the support washed again with pyridine (4 times 5 mL).

The deprotection, coupling, and capping as described in the above paragraph are repeated with three additional PNA monomers: N<sup>6</sup>-benzyloxycarbonyl-1-(t-butyloxycarbonyl-aminoethylglycyl)adenine, N<sup>4</sup>-benzyloxycarbonyl-1-(t-butyloxycarbonyl-aminoethylglycyl)cytosine, and 1-(t-butyloxycarbonyl-aminoethylglycyl)thymine.  
10

The deprotection, coupling, and capping are then repeated once more, but the monomer used in this case is 5'-(tertbutyldiphenylsilyl)-3'-carboxymethylthymidine. After the  
15 capping reaction, the resin is washed with pyridine (3 times 3 mL) and DMF (3 times 3 mL). Anhydrous THF (3 mL) is added to the flask followed by 45 microL of 70% (v/v) HF/pyridine. After shaking overnight the resin is washed with THF (5 times 3 mL), DMF (3 times, 3 mL), acetonitrile (5 times 3 mL), and  
20 DCM (5 times 3 mL). The resin is then dried by blowing with argon.

#### EXAMPLE 4

T(5'-amino)-G<sup>PAC</sup>-C<sup>PAC</sup>-A<sup>PAC</sup>-T-T(3'-carboxy)-T(p)-C<sup>Z</sup>(p)-A<sup>Z</sup>(p)-G<sup>Z</sup>(p)-Gly-O-Resin

25 5'-Hydroxy-T(3'-carboxy)-G<sup>Z</sup>(p)-C<sup>Z</sup>(p)-A<sup>Z</sup>(p)-T(p)-Gly-O-Resin (10 microequivalents, example 3) is placed in a DNA synthesis column. Standard DNA synthesis (Example 1) is performed with phosphoramidites containing phenoxyacetyl protecting groups on the exocyclic amines, 2-cyanoethyl groups  
30 on the phosphorous, and 4,4'-dimethoxytrityl groups on the 5'-hydroxyl. The 5'-terminal phosphoramidite coupled is 5'-(monomethoxytritylamino)thymidine-3'-(N,N-diisopropylamino-2-cyanoethyl)phosphoramidite. The monomethoxytrityl group is removed by the standard automated treatment with dichloroacetic  
35 acid in DCM. After washing with DCM, the resin is dried under reduced pressure.



## EXAMPLE 5

N-Acetylglycyl-T(p)-T(p)-C<sup>z</sup>(p)-T(p)-C<sup>z</sup>(p)-G<sup>z</sup>(p)-C<sup>z</sup>(p)-COOH

Hydroxymethyl polystyrene resin (115 mg, 75 micro-equivalents) was placed in a solid-phase peptide synthesis vessel. The support was washed with DCM (3 times 3 mL), DMF (3 times 3 mL), pyridine (3 times 3 mL), and DMF again (2 times 3 mL). To a vial was added N<sup>4</sup>-benzyloxycarbonyl-1-(*t*-butyloxycarbonyl-aminoethylglycyl)cytosine (151 mg, 300 micromoles) and O-(benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (87 mg, 270 micromoles). N,N-Dimethylformamide (1.25 mL) and pyridine (1.25 mL) were added to the vial followed by N,N-diisopropylethylamine (105 microL, 600 micromoles). The vial was shaken until all solids were dissolved. After one minute the contents of the vial were added to the peptide synthesis vessel and shaken for 30 minutes. The reaction solution was then drained away and the support washed with DMF (4 times 3 mL). The coupling of the C monomer was repeated as above. The resin was then capped by addition of 10% N-benzyloxycarbonyl-N'-methyl-imidazole triflate in N,N-dimethylformamide (2.25 mL) followed by shaking for 5 minutes. The resin was finally washed with pyridine (4 times 3 mL) and was then ready for chain extension.

The support was washed with 50% DMF/DCM (4 times 3 mL) and then treated twice with 5% *m*-cresol in trifluoroacetic acid (3 mL) with shaking for two minutes each time. The support was washed again with 50% DMF/DCM (4 times 3 mL) and then with pyridine (5 times 3 mL). To a vial were added N<sup>2</sup>-benzyloxycarbonyl-1-(*t*-butyloxycarbonyl-aminoethylglycyl)guanine (163 mg, 300 micromoles) and O-(benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (87 mg, 270 micromoles). N,N-Dimethylformamide (1.25 mL) and pyridine (1.25 mL) were added to the vial followed by N,N-diisopropylethylamine (105 microL, 600 micromoles). The vial was shaken until all solids were dissolved. After one minute the contents of the vial were added to the peptide synthesis vessel and shaken for 20 minutes. The reaction solution was then drained away and the support washed with pyridine (5 times 3 mL). Remaining free amine was capped

by addition of a 10% solution of N-benzyloxycarbonyl-N'-methylimidazole triflate in N,N-dimethylformamide (2.25 mL). After shaking for five minutes, the capping solution was drained and the support washed again with pyridine (4 times 3 mL).

5           The deprotection, coupling, and capping as described in the above paragraph were repeated in the following order with the PNA monomers: N<sup>4</sup>-benzyloxycarbonyl-1-(t-butyloxycarbonyl-aminoethylglycyl)cytosine, and 1-(t-butyloxycarbonyl-aminoethylglycyl)thymine, N<sup>4</sup>-benzyloxycarbonyl-1-(t-butyloxy-  
10 carbonylaminoethylglycyl)cytosine, 1-(t-butyloxycarbonyl-aminoethylglycyl)thymine, 1-(t-butyloxycarbonylaminoethylglycyl)-thymine, and then with N-acetylglycine. After the last capping reaction, the resin was washed with pyridine (5 times 3 mL) and DCM (4 times 3 mL). The resin was then dried by blowing with  
15 argon.

A portion (29 mg, 10 microequivalents) of the resin was placed in a solid phase peptide synthesis vessel and tetrahydrofuran (2.5 mL) was added, followed by a solution of aqueous saturated potassium bicarbonate (0.25 mL) and tetra-  
20 butylammonium hydrogen sulphate (34 mg, 100 micromoles). The reaction was then shaken for 14 hours at room temperature. Water (1 mL) was added to the reaction, causing precipitation of a white solid. The liquid was filtered off and saved. The resin and white solid were then washed with additional water (1  
25 mL) which was added to the first wash. Concentration to dryness under reduced pressure resulted in a white solid mixed with a pink oil. Water (6 mL) was added and the pH was adjusted to 2 with solid KHSO<sub>4</sub>. The liquid and suspended yellow solid were then transferred to Eppendorf tubes and the  
30 solid was spun down. The solvent was removed and the residual yellow solid was redissolved in 30% acetonitrile in water containing 0.1% TFA. Reverse phase chromatography resulted in the desired product (2.6 mg, 1 micromole): molecular mass= 2498 (electrospray mass spectrometry).

## EXAMPLE 6

N-Acetylglycyl-T(p)-T(p)-C(p)-T(p)-C(p)-G(p)-C(p)-T(5'-amino)-  
G-C -A-T-T(3'-carboxy)-T(p)-C(p)-A(p)-G(p)-Gly-COOH

T(5'-Amino)-G<sup>PAC</sup>-C<sup>PAC</sup>-A<sup>PAC</sup>-T-T(3'-carboxy)-T(p)-C<sup>Z</sup>(p)-  
5 A<sup>Z</sup>(p)-G<sup>Z</sup>(p)-Gly-O-resin (5 microequivalents, Example 3) is  
placed in a solid-phase peptide synthesis vessel. The resin is  
washed with DCM (3 times 3 mL), DMF (3 times 3 mL), and  
pyridine (3 times 3 mL). To a vial are added N-Acetylglycyl-  
T(p)-T(p)-C<sup>Z</sup>(p)-T(p)-C<sup>Z</sup>(p)-G<sup>Z</sup>(p)-C<sup>Z</sup>(p)-COOH (10 micromoles,  
10 prepared as in example 5) and O-(benzotriazol-1-yl)-1,1,3,3-  
tetramethyluronium tetrafluoroborate (9 micromoles). N,N-  
Dimethylformamide (0.3 mL) and pyridine (0.3 mL) are added to  
the vial followed by N,N-diisopropylethylamine (20 micromoles).  
The vial is shaken until all solids are dissolved. After one  
15 minute the contents of the vial are added to the peptide  
synthesis vessel and shaken for 4 hours. The reaction solution  
is then drained away and the support washed five times with  
pyridine.

Tetrahydrofuran (2 mL) is added to the resin, followed  
20 by a solution of aqueous saturated potassium bicarbonate (0.2  
mL) and tetrabutylammonium hydrogen sulphate (27 mg, 80 micro-  
moles). The reaction is shaken for 14 hours at room tempera-  
ture. The solution is then drained and kept. The resin is  
washed with 50% tetrahydrofuran/water (3 times 1 mL) and with  
25 water (3 times 2 mL). The wash solutions are added to the  
reaction solution and concentrated under reduced pressure to  
remove organics - concentration is stopped at a final volume of  
2 milliliters. Inorganics are removed by gel filtration. The  
crude material is dissolved in aqueous 15 mM acetic acid (10  
30 mL) and alternately degassed under vacuum and back-filled with  
nitrogen four times. Palladium on BaSO<sub>4</sub> (5%, 30 mg) is added  
and the solution is stirred at RT °C for 2 hours. The catalyst  
is removed by filtration and the product is then purified by  
reverse phase HPLC.

## EXAMPLE 7

5'-Amino-deoxythymidylyl-(3'-5')-3'-O-*tert*butyldiphenylsilyl-deoxythymidine (H<sub>2</sub>N-T-T)

3'-*tert*Butyldiphenylsilyldeoxythymidine (58 mg, 120  
5 micromoles) and 5'-(*p*-methoxytriphenylmethylamino)-3'-[O-(2-cyanoethyl)-*N,N*-diisopropylaminophosphoramidyl]deoxythymidine (71 mg, 100 micromoles) were put in separate 10 mL round-bottom flasks and each co-evaporated once with anhydrous pyridine (2 mL) and twice with anhydrous acetonitrile (1.5 mL). The com-  
10 pounds were then each dissolved in anhydrous acetonitrile (0.75 mL) and combined. The reaction was initiated by the addition of a solution of 0.4 M 1H-tetrazole in anhydrous acetonitrile (1 mL, 400 micromoles tetrazole). After stirring 50 minutes at room temperature the reaction was quenched by pouring into an  
15 oxidizing solution (10 mL of 0.43% I<sub>2</sub> in 90.54% THF, 0.41% pyridine, and 9.05% water).

The oxidation reaction was stirred an additional 40 minutes and poured into a separatory funnel containing dichloromethane (50 mL) and water (20 mL). Residual iodine was removed  
20 by washing the organic layer with a solution of 0.3% sodium metabisulfite in water (95 mL). The organic layer was then concentrated to a yellow oil by rotary evaporation under reduced pressure. The yellow oil was co-evaporated with toluene (2 x 15 mL) under reduced pressure to remove residual  
25 pyridine.

The crude material was then dissolved in dichloromethane (6 mL) and the trityl group was removed by addition of a solution of 3% trichloroacetic acid in dichloromethane (3 mL). After stirring 15 minutes at room temperature the  
30 reaction was quenched by pouring into a separatory funnel containing cold (4 °C) saturated aqueous sodium bicarbonate (10 mL). Additional dichloromethane (20 mL) was added and the organic layer was separated. A residual emulsion in the aqueous layer was broken up by addition of more dichloromethane (20  
35 mL). The two organic layers were then combined and concentrated to dryness under reduced pressure. The desired product was purified from the resulting crude tan solid by preparative

silica TLC run in 20% (v/v) ethanol/chloroform, 0.2% N,N-diisopropylethylamine (49 mg, 63 micromoles, 63%):  $R_f$  (20% (v/v) ethanol/chloroform, 0.2% N,N-diisopropylethylamine) = 0.05;  $^1\text{H}$  NMR (200 MHz, MeOH- $d_4$ )  $\delta$  7.65 (m, 4H), 7.4 (m, 8H), 6.45 (m, 1H), 5.95 (m, 1H), 4.6 (m, 1H), 4.1 (m, 2H), 3.9 (m, 1H), 3.6 (m, 1H), 3.2 (m, 1H), 2.9 (m, 2H), 2.5-2.0 (m, 4H), 1.89 (s, 6H), 1.1 (s, 9H);  $^{31}\text{P}$  NMR (MeOH- $d_4$ )  $\delta$  0.85; ESMS  $m/e$  782.

**EXAMPLE 8****10 N,N-Diisopropylethylammonium salt of DMT-O-T(pna)-CONH-T-T**

$\text{H}_2\text{N-TpT}$  (25 mg, 30 micromoles) was dissolved in 1:1 DMF/pyridine (0.8 mL). To a separate vial were added 1-[O-4,4'-dimethoxytrityl-hydroxyethylglycyl]thymine (23.5 mg, 40 micromoles) and O-(benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (11.6 mg, 36 micromoles). The vial's contents were dissolved in 1:1 DMF/pyridine (0.8 mL) and N,N-diisopropylethylamine (14  $\mu\text{L}$ , 80 micromoles). After 5 minutes the activated ester solution was added to the  $\text{H}_2\text{N-TpT}$  solution. The reaction was stirred at room temperature for 80 minutes and quenched by the addition of ethyl alcohol (0.5 mL). After an additional 150 minutes the reaction mixture was concentrated to dryness under reduced pressure. The resulting solid was purified by preparative silica TLC run in 20% (v/v) ethanol/chloroform, 0.2% N,N-diisopropylethylamine (27 mg, 20 micromoles, 67%):  $R_f$  (20% (v/v) ethanol/chloroform, 0.2% N,N-diisopropylethylamine) = 0.18;  $^1\text{H}$  NMR (200 MHz, DMSO- $d_6$ )  $\delta$  11.35 (m, 3H), 8.95 (br s, 0.3H), 8.72 (br s, 0.7H), 7.79 (m, 2H), 7.61-7.19 (m, 22H), 6.91 (m, 4H), 6.36 (m, 1H), 6.03 (m, 1H), 4.78 (m, 2H), 4.59 (s, 1H), 4.41 (m, 3H), 4.20 (s, 1H), 3.93 (m, 2H), 3.65 (s, 2H), 3.18 (br s, 3H), 2.97 (m, 2H), 3.74 (s, 6H), 3.42 (m, 4H), 2.01 (br s, 4H), 1.77 (m, 7H), 1.62 (s, 2H), 1.03 (m, 15H);  $^{13}\text{C}$  NMR (DMSO- $d_6$ ): 167.9, 164.6, 163.8, 158.2, 150.5, 144.9, 143.0, 136.1, 135.7, 132.9, 130.2, 129.8, 128.1, 127.8, 126.8, 123.4, 118.6, 113.4, 110.7, 110.1, 107.9, 86.3, 84.0, 83.0, 74.8, 74.5, 61.3, 56.2, 55.1, 47.5, 26.8, 18.7, 12.1;  $^{31}\text{P}$  NMR (DMSO- $d_6$ )  $\delta$  -0.2, -1.05; ESMS  $m/e$  1351.

**EXAMPLE 9****N,N-Diisopropylethylammonium salt of tBoc-A<sup>z</sup>(pna)-CONH-T-T**

H<sub>2</sub>N-TpT (19 mg, 24 micromoles) was dissolved in 1:1 DMF/pyridine (0.65 mL). To a separate vial were added N<sup>6</sup>-5 benzyloxycarbonyl-1-(t-butyloxycarbonyl-aminoethylglycyl)-adenine (12.7 mg, 24 micromoles) and O-(benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (7.1 mg, 22 micromoles). The vial's contents were dissolved in 1:1 DMF/pyridine (0.65 mL) and N,N-diisopropylethylamine (8.4 10 microL, 48 micromoles). After 2 minutes the activated ester solution was added to the H<sub>2</sub>N-TpT solution. The reaction was stirred at room temperature for 105 minutes and quenched by the addition of ethyl alcohol (0.5 mL). After an additional 120 minutes the reaction mixture was concentrated to dryness under 15 reduced pressure. The resulting solid was purified by preparative silica TLC run in 20% (v/v) ethanol/chloroform, 0.2% N,N-diisopropylethylamine (6 mg, 5 micromoles, 21%): R<sub>f</sub> (20% (v/v) ethanol/chloroform, 0.2% N,N-diisopropylethylamine) = 0.07; <sup>1</sup>H NMR (200 MHz, DMSO-d<sub>6</sub>) δ 11.37 (s, 1H), 11.22 (s, 1H), 10.64 20 (br s, 1H), 9.17 (br s, 0.3H), 8.90 (br s, 0.7H), 8.59 (m, 2H), 8.30 (m, 1H), 7.80 (m, 1H), 7.58 (s, 3H), 7.38 (m, 12H), 7.16 (m, 1H), 6.36 (m, 1H), 6.04 (m, 1H), 5.43 (m, 1H), 5.32 (s, 1H), 5.23 (s, 2H), 5.1 (s, 1H), 4.42 (m, 3H), 4.19 (m, 1H), 3.98 (s, 1H), 3.87 (m, 3H), 3.77 (m, 1H), 3.66 (m, 1H), 3.02 25 (m, 2H), 2.68 (m, 1H), 2.03 (m, 4H), 1.74 (m, 6H), 1.02 (m, 30H); <sup>31</sup>P NMR (DMSO-d<sub>6</sub>) δ -0.01, -0.8.

**EXAMPLE 10****1-(t-Butyloxycarbonyl-aminoethylglycyl)thymine, ethyl ester**

1-(t-butyloxycarbonyl-aminoethylglycyl)thymine (300 30 mg, 780 micromoles) was dissolved in 50% DMF/pyridine (3.0 mL) and N,N-diisopropylethylamine (0.25 mL, 1.44 mmoles) was added. After stirring 5 minutes O-(benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (350 mg, 1.1 mmoles) was added to give light orange solution. The reaction was stirred 35 30 minutes after which absolute ethanol (0.75 mL, 4.26 mmoles) was added. After stirring an additional 90 minutes the reac-

tion mixture was concentrated to an oil under reduced pressure. The oil was dissolved in ethyl acetate (30 mL) and cooled to 5 °C. The pure product precipitated as a white solid which was collected by filtration (289 mg, 701 micromoles, 90%); ; <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) d 8.33 (br s, 1H), 7.02 (s, 0.3H), 6.97 (s, 0.7H), 5.58 (m, 1H), 4.59 (s, 1.4H), 4.43 (s, 0.6H), 4.1 (s, 2H), 3.54 (m, 2H), 3.33 (m, 2H), 1.92 (s, 3H), 1.47 (s, 9H).

**EXAMPLE 11****TBDPS-T-CONH-T(pna)-OEt**

10           The ethyl ester of 1-(t-Butyloxycarbonyl-amino-ethylglycyl)thymine (30 mg, 72 microMol) was dissolved in 1.0 mL of trifluoroacetic acid and stirred at RT for 30 minutes. This was concentrated *in vacuo* and then co-evaporated with 5 mL of toluene twice. The 5'-O-*tert*butyl-15 diphenylsilyl-3'-carboxymethyldeoxyribothymidine (25 mg, 48 microMol) was dissolved in 0.400 mL of a 1:1 DMF/pyridine solution. To this solution was added TBTU (21 mg, 65 microMol) and N,N-diisopropyl ethyl amine (25 microL, 144 microMol). The reaction became a pale orange color and was 20 stirred for 30 minutes. The amine from the TFA deprotection step was dissolved in 0.6 mL of DMF/Pyridine, added to the activated carboxythymidine solution and stirred at room temperature for one hour. TLC analysis (20% MeOH/DCM) indicated that all of the activated acid was consumed. The 25 solution was concentrated *in vacuo* to an oil. The oil was purified on a 2 mm preparative TLC Plate (20 mm X 20 mm) with 20 % MeOH/DCM as the eluting solvent. The least polar fraction contained the PNA-DNA chimera providing the desired product as a white solid (25 mg, 36 micromoles 30 50%); <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) d 9.8 (br s, 1H), 9.6 (br s, 1 H), 7.7 (m, 4 H), 7.3 (m, 9 H), 7.0 (dd, 1 H), 6.2 (m, 1 H), 4.5-3.4 (12 H), 2.9 (m, 1 H), 2.5-2.1 (m, 4 H), 1.5 (s, 3 H), 1.3 (d, 6 H), 1.1 (s, 9 H); <sup>13</sup>C NMR (CDCl<sub>3</sub>): d11.764, 12.083, 12.391, 14.144, 26.796, 27.055, 29.708, 35.232, 35 37.177, 37.788, 38.932, 48.298, 61.486, 64.854, 84.476,

85.018, 111.110, 127.711, 129.980, 135.407, 135.654, 140.976, 150.835, 151.555, 167.416, 172.192 ; ESMS m/e 817.

#### EXAMPLE 12

##### T-CONH-T(pna) -OEt

5           The above dimer (30 mg, 0.058 mMol) was de-silylated by dissolving in 1 ml dry THF and cooled to 0 °C. To this was added 20 mL of 70% HF/Pyridine and 10 mL of a 1 M solution of tetrabutyl ammonium fluoride was added and the reaction mixture stirred overnight. TLC (10% MeOH/DCM)  
10 indicated the reaction was complete. The solution was quenched with 1 ml of saturated NaHCO<sub>3</sub> and stirred until the gas evolution ceased. The aqueous layer was diluted with an additional 5 ml of water and extracted 2 X with 3 ml of ethyl acetate. The organic layers were combined and  
15 discarded. The aqueous layer was evaporated to dryness resulting in a mixture of the deprotected dimer and NaHCO<sub>3</sub>. The mixture was suspended in methanol and purified on two 20 X 20 0.5 mm preparative TLC plates eluting with 30 % ethanol in chloroform. After the plates finished eluting,  
20 they were dried and the fluorescent band scraped and extracted. The extract was filtered and evaporated to yield 12 mg (56 % yield) of the deprotected dimer that was contaminated with a small amount of tetrabutylammonium fluoride. <sup>1</sup>H(CD<sub>3</sub>OD): 1.0-1.5 (mm, 10 H); 1.5 (m, 2 H); 1.9  
25 (s, 6 H); 2.1-2.8 (mm, 6 H); 3.2-4.0 (mm, 15 H); 4.1-4.4 (m, 4 H); 4.7 (s, 1 H); 6.1 (m, 1 H); 7.3 (s, 1 H); 8.0 (s, 1 H).

#### EXAMPLE 13

(5'-DMT)-A<sup>2</sup>-T-(3'-carboxy)-T(pna) (including cyanoethoxy  
30 protected phosphodiester linkage)

The deprotected dimer of Example 12 (12 mg, .0207 mmol) was co-evaporated twice with anhydrous pyridine and twice with anhydrous acetonitrile. The resulting white solid was dissolved in 3 ml of 1:1 acetonitrile:DMF. To  
35 this solution was added 1 ml of a 0.1 M solution of adeno-



sine phosphoramidite and 1 ml of 0.4 M 1H-tetrazole solution. This was stirred at ambient temperature for 1 hr, and then an additional 1 ml of amidite was added and stirring continued for an additional hour. At the end of 5 that time 10 ml of oxidizing solution (0.43% I<sub>2</sub> in 90.54% THF, 0.41% pyridine, and 9.05% water) was added and the reaction stirred for 1 hour. The reaction was quenched with 25 ml of a 1 M solution of sodium bisulfite solution. This solution was extracted with chloroform 2 X 20 ml and 10 the combined extracts were washed with another 25 ml portion of bisulfite solution, resulting in a slightly yellow organic phase. The chloroform solution was dried over magnesium sulfate and concentrated to a yellow oil. The mixture was purified using 20 X 20 cm preparative TLC 15 plates (2, .5 mm coating) eluting with 20% acetone in dichloromethane. The diastereomeric mixture of trimer was isolated as an oil weighing 25 mg for a 93 % yield; <sup>1</sup>H (CDCl<sub>3</sub>): 1.2 (m, 13 H); 2.5-3.2 (mm 5 H); 3.4 (m, 4 H); 3.7 (s, 6H); 4.1 (m, 1 H); 4.4 (m, 1 H); 5.2 (m, 1 H); 6.5 (m, 20 1 H); 6.8 (m, 4 H); 7.3 (m, 10 H); 7.5 (m, 3 H); 8.0 (d, 2 H); 8.2 (d, 2 H); 8.7 (s, 1 H); 9.1 (s, 1 H); <sup>31</sup>P (CDCl<sub>3</sub>): 8.247, 8.116.

#### EXAMPLE 14

##### Stability of PNA oligomers to NH<sub>4</sub>OH deprotection conditions.

25 In the first case a PNA oligomer containing a free amino terminus (H-TAT-TCC-GTC-ATC-GCT-CCT-CA-Lys-NH<sub>2</sub>) (all PNA) was dissolved in 70% concentrated NH<sub>4</sub>OH. The reaction was incubated at 23 °C and aliquots were examined by reverse phase HPLC at the time points indicated below. 30 In the second experiment a PNA oligomer with a glycyll-capped amino terminus (H-Gly-TGT-ACG-TCA-CAA-CTA-Lys-NH<sub>2</sub>) (all PNA) was dissolved in 90% concentrated NH<sub>4</sub>OH and heated in a sealed flask at 55 °C.

The NH<sub>4</sub>OH stability of the PNA oligomer 35 containing a free amino terminus was insufficient to allow the removal of base protecting groups from the PNA/DNA

chimera. Capping the amino terminus with a glycyI group greatly increased the stability of the PNA to aqueous base. The glycyI-capped PNA demonstrated only minimal degradation at the 11 hour time point with 15% decomposition after 23 hours. The glycyI capped PNA is completely stable to conditions used to remove the phenoxyacetyl protecting group and relatively stable to those used for the standard DNA base protecting groups (benzoyl and isobutyryl amides). The results are shown in Table 1.

10

TABLE 1

hours	Remaining <u>uncapped</u> PNA, 23°C	Remaining <u>capped</u> PNA, 55°C
1	97	100
2	92	99
4	85	
15 5		97
6	75	
8	60	
11		92
23		85

20 **EXAMPLE 15**

**Macromolecule Having Peptide Nucleic Acids Regions Flanking  
A Central 2'-Deoxy Phosphorothioate Oligonucleotide Region  
Joined via Amine and Ester linkages**

A first region of peptide nucleic acids is prepared as per Example 2 above. The peptide nucleic acids is prepared from the C terminus towards the N terminus using monomers having protected amine groups. Following completion of the first peptide region, the terminal amine blocking group is removed and the resulting amine reacted

with a 3'-C-(formyl)-2',3'-dideoxy-5'-trityl nucleotide prepared as per the procedure of Vasseur, *et. al.*, *J. Am. Chem. Soc.* **1992**, *114*, 4006. The condensation of the amine with the aldehyde moiety of the C-formyl nucleoside is effected as per the conditions of the Vasseur, *ibid.*, to yield an intermediate imine linkage. The imine linkage is reduced under reductive alkylation conditions of Vasseur, *ibid.*, with HCHO/NaBH<sub>3</sub>CN/AcOH to yield the nucleoside connected to the peptide nucleic acid via an methylalkylated amine linkage. An internal 2'-deoxy phosphorothioate nucleotide region is then continued from this nucleoside as per the protocols of Example 1. Peptide synthesis for the second peptide region is commenced by reaction of the carboxyl end of the first peptide nucleic acid of this second region with the 5' hydroxy of the last nucleotide of the DNA region following removal of the dimethoxytrityl blocking group on that nucleotide. Coupling is effected via EDC in pyridine to form an ester linkage between the peptide and the nucleoside. Peptide synthesis is then continued to complete the second peptide nucleic acid region.

#### EXAMPLE 16

##### Macromolecule Having Peptide Nucleic Acids Regions Flanking A Central 2'-Deoxy Phosphoroselenate Oligonucleotide Region

The synthesis of Example 15 is repeated except for introduction of the phosphoroselenate linkages in the 2'-deoxynucleotide portion of the macromolecule, oxidation is effected with 3H-1,2-benzothiaseleno-3-ol as per the procedure reported by Stawinski, *et al.*, *Tenth International Roundtable: Nucleosides, Nucleotides and Their Biological Evaluation*, September 16-20, 1992, Abstracts of Papers, Abstract 80.

**EXAMPLE 17****Macromolecule Having Peptide Nucleic Acids Regions Flanking  
A Central 2'-Deoxy Phosphorodithioate Oligonucleotide  
Region**

5           The synthesis of Example 15 is repeated except  
for introduction of the phosphorodithioate linkages in the  
2'-deoxynucleotide portion of the macromolecule, oxidiza-  
tion is effected utilizing the procedures of Beaton, et.  
al., Chapter 5, Synthesis of oligonucleotide phosphorodi-  
10 thioates, page 109, *Oligonucleotides and Analogs, A  
Practical Approach*, Eckstein, F., Ed.; The Practical  
Approach Series, IRL Press, New York, 1991.

**PROCEDURE 1****ras-Luciferase Reporter Gene Assembly**

15           The ras-luciferase reporter genes were assembled  
using PCR technology. Oligonucleotide primers were synthe-  
sized for use as primers for PCR cloning of the 5'-regions  
of exon 1 of both the mutant (codon 12) and non-mutant  
(wild-type) human H-ras genes. The plasmids pT24-C3,  
20 containing the c-H-ras1 activated oncogene (codon 12,  
GGC→GTC), and pbc-N1, containing the c-H-ras proto-onco-  
gene, were obtained from the American Type Culture Col-  
lection (Bethesda, MD). The plasmid pT3/T7 luc, containing  
the 1.9 kb firefly luciferase gene, was obtained from  
25 Clontech Laboratories (Palo Alto, CA). The oligonucleo-  
tide PCR primers were used in standard PCR reactions using  
mutant and non-mutant H-ras genes as templates. These  
primers produce a DNA product of 145 base pairs corres-  
ponding to sequences -53 to +65 (relative to the transla-  
30 tional initiation site) of normal and mutant H-ras, flanked  
by NheI and HindIII restriction endonuclease sites. The  
PCR product was gel purified, precipitated, washed and  
resuspended in water using standard procedures.

          PCR primers for the cloning of the *P. pyralis*  
35 (firefly) luciferase gene were designed such that the PCR  
product would code for the full-length luciferase protein

with the exception of the amino-terminal methionine residue, which would be replaced with two amino acids, an amino-terminal lysine residue followed by a leucine residue. The oligonucleotide PCR primers used for the 5 cloning of the luciferase gene were used in standard PCR reactions using a commercially available plasmid (pT3/T7-Luc) (Clontech), containing the luciferase reporter gene, as a template. These primers yield a product of approximately 1.9 kb corresponding to the luciferase gene, 10 flanked by unique HindIII and BssHII restriction endonuclease sites. This fragment was gel purified, precipitated, washed and resuspended in water using standard procedures.

To complete the assembly of the ras-luciferase 15 fusion reporter gene, the ras and luciferase PCR products were digested with the appropriate restriction endonucleases and cloned by three-part ligation into an expression vector containing the steroid-inducible mouse mammary tumor virus promotor MMTV using the restriction endonucleases 20 NheI, HindIII and BssHII. The resulting clone results in the insertion of H-ras 5' sequences (-53 to +65) fused in frame with the firefly luciferase gene. The resulting expression vector encodes a ras-luciferase fusion product which is expressed under control of the steroid-inducible 25 MMTV promoter. These plasmid constructions contain sequences encoding amino acids 1-22 of activated (RA2) or normal (RA4) H-ras proteins fused in frame with sequences coding for firefly luciferase. Translation initiation of the ras-luciferase fusion mRNA is dependent upon the 30 natural H-ras AUG codon. Both mutant and normal H-ras luciferase fusion constructions were confirmed by DNA sequence analysis using standard procedures.

## PROCEDURE 2

### Transfection of Cells with Plasmid DNA

35 Transfections were performed as described by Greenberg, M.E., in *Current Protocols in Molecular Biology*,

(F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.A. Smith, J.G. Seidman and K. Strahl, eds., John Wiley and Sons, NY,) with the following modifications. HeLa cells were plated on 60 mm dishes at  $5 \times 10^5$  cells/dish. A total of 10  $\mu$ g or 12  $\mu$ g of DNA was added to each dish, of which 1  $\mu$ g was a vector expressing the rat glucocorticoid receptor under control of the constitutive Rous sarcoma virus (RSV) promoter and the remainder was ras-luciferase reporter plasmid. Calcium phosphate-DNA coprecipitates were removed after 16-20 hours by washing with Tris-buffered saline [50 mM Tris-Cl (pH 7.5), 150 mM NaCl] containing 3 mM EGTA. Fresh medium supplemented with 10% fetal bovine serum was then added to the cells. At this time, cells are pre-treated with the macromolecules of the invention prior to activation of reporter gene expression by dexamethasone.

### PROCEDURE 3

#### Treatment of Cells

Following plasmid transfection, cells are washed with phosphate buffered saline prewarmed to 37 °C and Opti-MEM containing 5  $\mu$ g/mL N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) is added to each plate (1.0 ml per well). Test compounds are added from 50  $\mu$ M stocks to each plate and incubated for 4 hours at 37 °C. Medium is removed and replaced with DMEM containing 10% fetal bovine serum and the appropriate test compound at the indicated concentrations and cells are incubated for an additional 2 hours at 37 °C before reporter gene expression is activated by treatment of cells with dexamethasone to a final concentration of 0.2  $\mu$ M. Cells are harvested and assayed for luciferase activity fifteen hours following dexamethasone stimulation.

**PROCEDURE 4****Luciferase Assays**

Luciferase is extracted from cells by lysis with the detergent Triton X-100 as described by Greenberg, M.E., 5 in *Current Protocols in Molecular Biology*, (F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.A. Smith, J.G. Seidman and K. Strahl, eds.), John Wiley and Sons, NY. A Dynatech ML1000 luminometer is used to measure peak luminescence upon addition of luciferin (Sigma) to 625  $\mu$ M. 10 For each extract, luciferase assays are performed multiple times, using differing amounts of extract to ensure that the data is gathered in the linear range of the assay.

**PROCEDURE 5****Melting Curves**

15 Absorbance vs temperature curves are measured at 260 nm using a Gilford 260 spectrophotometer interfaced to an IBM PC computer and a Gilford Response II spectrophotometer. The buffer contained 100 mM Na<sup>+</sup>, 10 mM phosphate and 0.1 mM EDTA, pH 7. Test compound concentration is 4  $\mu$ M for 20 each strand determined from the absorbance at 85°C and extinction coefficients calculated according to Puglisi and Tinoco, *Methods in Enzymol.* 1989, 180, 304-325.  $T_m$  values, free energies of duplex formation and association constants are obtained from fits of data to a two state model with 25 linear sloping baselines. Petersheim, M. and Turner, D.H., *Biochemistry* 1983, 22, 256-263. Reported parameters are averages of at least three experiments. For some test compounds, free energies of duplex formation are also obtained from plots of  $T_m^{-1}$  vs  $\log_{10}$  (concentration). Borer, 30 P.N., Dengler, B., Tinoco, I., Jr., and Uhlenbeck, O.C., *J. Mol. Biol.*, 1974, 86, 843-853.

**PROCEDURE 6****Gel Shift Assay**

The structured ras target transcript, a 47- 35 nucleotide hairpin containing the mutated codon 12, is

prepared and mapped as described in Lima et al., *Biochemistry* **1991**, 31, 12055-12061. Hybridization reactions are prepared in 20  $\mu$ l containing 100 mM sodium, 10 mM phosphate, 0.1 mM EDTA, 100 CPM of T7-generated RNA 5 (approximately 10 pM), and test compound ranging in concentration from 1 pM to 10  $\mu$ M. Reactions are incubated 24 hours at 37 °C. Following hybridization, loading buffer was added to the reactions and reaction products are resolved on 20% native polyacrylamide gels, prepared using 1045 mM tris-borate and 1 mM  $MgCl_2$  (TBM). Electrophoresis is carried out at 10 °C and gels are quantitated using a Molecular Dynamics Phosphorimager.

#### PROCEDURE 7

##### RNase H Analysis

15 RNase H assays are performed using a chemically synthesized 25-base oligoribonucleotide corresponding to bases +23 to +47 of activated (codon 12, G→U) H-ras mRNA. The 5' end-labeled RNA is used at a concentration of 20 nM and incubated with a 10-fold molar excess of test compound 20 in a reaction containing 20 mM tris-Cl, pH 7.5, 100 mM KCl, 10 mM  $MgCl_2$ , 1 mM dithiothreitol, 10  $\mu$ g tRNA and 4 U RNasin in a final volume of 10  $\mu$ l. The reaction components are preannealed at 37 °C for 15 minutes then allowed to cool slowly to room temperature. HeLa cell nuclear extracts are 25 used as a source of mammalian RNase H. Reactions are initiated by addition of 2  $\mu$ g of nuclear extract (5  $\mu$ l) and reactions are allowed to proceed for 10 minutes at 37 °C. Reactions are stopped by phenol/chloroform extraction and RNA components are precipitated with ethanol. Equal CPMs 30 are loaded on a 20% polyacrylamide gel containing 7M urea and RNA cleavage products are resolved and visualized by electrophoresis followed by autoradiography. Quantitation of cleavage products is performed using a Molecular Dynamics Densitometer.



**PROCEDURE 8****ras Transactivation Reporter Gene System**

The expression plasmid pSV2-oli, containing an activated (codon 12, GGC→GTC) H-ras cDNA insert under control of the constitutive SV40 promoter, was a gift from Dr. Bruno Tocque (Rhone-Poulenc Sante, Vitry, France). This plasmid is used as a template to construct, by PCR, a H-ras expression plasmid under regulation of the steroid-inducible mouse mammary tumor virus (MMTV) promoter. To obtain H-ras coding sequences, the 570 bp coding region of the H-ras gene is amplified by PCR. The PCR primers are designed with unique restriction endonuclease sites in their 5'-regions to facilitate cloning. The PCR product containing the coding region of the H-ras codon 12 mutant oncogene is gel purified, digested, and gel purified once again prior to cloning. This construction is completed by cloning the insert into the expression plasmid pMAMneo (Clontech Laboratories, CA).

The ras-responsive reporter gene pRDO53 is used to detect ras expression. Owen et al., *Proc. Natl. Acad. Sci. U.S.A.* 1990, 87, 3866-3870.

**PROCEDURE 9****Northern blot analysis of ras expression in vivo**

The human urinary bladder cancer cell line T24 is obtained from the American Type Culture Collection (Rockville MD). Cells are grown in McCoy's 5A medium with L-glutamine (Gibco BRL, Gaithersburg MD), supplemented with 10% heat-inactivated fetal calf serum and 50 U/ml each of penicillin and streptomycin. Cells are seeded on 100 mm plates. When they reached 70% confluency, they are treated with test compound. Plates are washed with 10 ml prewarmed PBS and 5 ml of Opti-MEM reduced-serum medium containing 2.5  $\mu$ l DOTMA. Test compound is then added to the desired concentration. After 4 hours of treatment, the medium is replaced with McCoy's medium. Cells are harvested 48 hours after test compound treatment and RNA is isolated using a

standard CsCl purification method. Kingston, R.E., in *Current Protocols in Molecular Biology*, (F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.A. Smith, J.G. Seidman and K. Strahl, eds.), John Wiley and Sons, NY.

5 The human epithelioid carcinoma cell line HeLa 229 is obtained from the American Type Culture Collection (Bethesda, MD). HeLa cells are maintained as monolayers on 6-well plates in Dulbecco's Modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and 100 U/ml  
10 penicillin. Treatment with test compound and isolation of RNA are essentially as described above for T24 cells.

Northern hybridization: 10 µg of each RNA is electrophoresed on a 1.2% agarose/formaldehyde gel and transferred overnight to GeneBind 45 nylon membrane  
15 (Pharmacia LKB, Piscataway, NJ) using standard methods. Kingston, R.E., in *Current Protocols in Molecular Biology*, (F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.A. Smith, J.G. Seidman and K. Strahl, eds.), John Wiley and Sons, NY. RNA is UV-crosslinked to the membrane. Double-  
20 stranded <sup>32</sup>P-labeled probes are synthesized using the Prime a Gene labeling kit (Promega, Madison WI). The ras probe is a SalI-NheI fragment of a cDNA clone of the activated (mutant) H-ras mRNA having a GGC-to-GTC mutation at codon-12. The control probe is G3PDH. Blots are prehybridized  
25 for 15 minutes at 68 °C with the QuickHyb hybridization solution (Stratagene, La Jolla, CA). The heat-denatured radioactive probe (2.5 x 10<sup>6</sup> counts/2 ml hybridization solution) mixed with 100 µl of 10 mg/ml salmon sperm DNA is added and the membrane is hybridized for 1 hour at 68 °C.  
30 The blots are washed twice for 15 minutes at room temperature in 2x SSC/0.1% SDS and once for 30 minutes at 60 °C with 0.1xSSC/0.1%SDS. Blots are autoradiographed and the intensity of signal is quantitated using an ImageQuant PhosphorImager (Molecular Dynamics, Sunnyvale, CA).  
35 Northern blots are first hybridized with the ras probe, then stripped by boiling for 15 minutes in 0.1x SSC/0.1%SDS

and rehybridized with the control G3PDH probe to check for correct sample loading.

#### PROCEDURE 10

##### Inhibition of proliferation of cancer cells and use as controls for chemotherapeutic agent test

Cells are cultured and treated with test compound essentially as described in Example 9. Cells are seeded on 60 mm plates and are treated with test compound in the presence of DOTMA when they reached 70% confluency. Time course experiment: On day 1, cells are treated with a single dose of test compound at a final concentration of 100 nM. The growth medium is changed once on day 3 and cells are counted every day for 5 days, using a counting chamber. Dose-response experiment: Various concentrations of test compound (10, 25, 50, 100 or 250 nM) are added to the cells and cells are harvested and counted 3 days later. The active compounds of the invention can then be used standards in this same screen for screening of other chemotherapeutic agents.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANTS: Philip Dan Cook
- (ii) TITLE OF INVENTION: PNA-DNA-PNA Chimeric  
Macromolecules
- (iii) NUMBER OF SEQUENCES: 4
- (iv) CORRESPONDENCE ADDRESS:  
(A) ADDRESSEE: Woodcock Washburn Kurtz  
Mackiewicz and Norris  
(B) STREET: One Liberty Place - 46th Floor  
(C) CITY: Philadelphia  
(D) STATE: PA  
(E) COUNTRY: U.S.A.  
(F) ZIP: 19103
- (v) COMPUTER READABLE FORM:  
(A) MEDIUM TYPE: Floppy disk, 1.44 Mb storage  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: WordPerfect 5.1
- (vi) CURRENT APPLICATION DATA:  
(A) APPLICATION NUMBER: n/a  
(B) FILING DATE: herewith  
(C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:  
(A) APPLICATION NUMBER: US92/11339  
(B) FILING DATE: December 23, 1992
- (viii) ATTORNEY/AGENT INFORMATION:  
(A) NAME: John W. Caldwell  
(B) REGISTRATION NUMBER: 28,937  
(C) REFERENCE/DOCKET NUMBER: ISIS-1236
- (ix) TELECOMMUNICATION INFORMATION:  
(A) TELEPHONE: 215-568-3100  
(B) TELEFAX: 215-568-3439

## 35 (2) INFORMATION FOR SEQ ID NO: 1:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 10  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- (iv) ANTI-SENSE: yes
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

TGCATTTCAG

10

## (2) INFORMATION FOR SEQ ID NO: 2:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 17  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (iv) ANTI-SENSE: yes

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

10 TTCTCGCTGC ATTTCAG

17

## (2) INFORMATION FOR SEQ ID NO: 3:

## (i) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 20  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (iv) ANTI-SENSE: yes

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

TATTCCGTCA TCGCTCCTCA

20

## 20 (2) INFORMATION FOR SEQ ID NO: 4:

## (i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 15  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (iv) ANTI-SENSE: yes

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

TGTACGTCAC AACTA

15

2025 RELEASE UNDER E.O. 14176

## WHAT IS CLAIMED IS:

1. A macromolecule of the structure:

PNA-DNA-PNA

wherein:

said DNA comprises at least one 2'-deoxynucleotide; and

each of said PNAs comprise at least one peptide nucleic acid subunit.

2. A macromolecule of claim 1 wherein said PNA-DNA-PNA macromolecule is capable of specifically hybridizing to a strand of nucleic acid.

3. A macromolecule of claim 2 wherein said stand of nucleic acid is a RNA strand.


4. A macromolecule of claim 1 wherein:  
said DNA includes at least three 2'-deoxynucleotides linked together in a sequence; and  
each PNA includes at least two peptide nucleic acid subunits.

5. A macromolecule of claim 1 wherein said 2'-deoxynucleotide is a phosphodiester, a phosphorothioate or a phosphorodithioate nucleotide.

6. A macromolecule of claim 1 wherein said DNA includes at least three 2'-deoxynucleotides linked together in a sequence by phosphodiester, phosphorothioate or phosphorodithioate linkages.

7. A macromolecule of claim 1 wherein each of said PNAs comprises a compound of the formula (I):

2025 RELEASE UNDER E.O. 14176



(I)

wherein:

$n$  is at least 2,

each of  $L^1-L^n$  is independently selected from the group consisting of hydrogen, hydroxy,  $(C_1-C_4)$ alkanoyl, naturally occurring nucleobases, non-naturally occurring nucleobases, aromatic moieties, DNA intercalators, nucleobase-binding groups, heterocyclic moieties, and reporter ligands, at least one of  $L^1-L^n$  being a naturally occurring nucleobase, a non-naturally occurring nucleobase, a DNA intercalator, or a nucleobase-binding group;

each of  $C^1-C^n$  is  $(CR^6R^7)_y$  where  $R^6$  is hydrogen and  $R^7$  is selected from the group consisting of the side chains of naturally occurring alpha amino acids, or  $R^6$  and  $R^7$  are independently selected from the group consisting of hydrogen,  $(C_2-C_6)$ alkyl, aryl, aralkyl, heteroaryl, hydroxy,  $(C_1-C_6)$ alkoxy,  $(C_1-C_6)$ alkylthio,  $NR^3R^4$  and  $SR^5$ , where  $R^3$  and  $R^4$  are as defined above, and  $R^5$  is hydrogen,  $(C_1-C_6)$ alkyl, hydroxy-, alkoxy-, or alkylthio- substituted  $(C_1-C_6)$ alkyl, or  $R^6$  and  $R^7$  taken together complete an alicyclic or heterocyclic system;

each of  $D^1-D^n$  is  $(CR^6R^7)_z$  where  $R^6$  and  $R^7$  are as defined above;


each of  $y$  and  $z$  is zero or an integer from 1 to 10, the sum  $y + z$  being greater than 2 but not more than 10;

each of  $G^1-G^{n-1}$  is  $-NR^3CO-$ ,  $-NR^3CS-$ ,  $-NR^3SO-$  or  $-NR^3SO_2-$ , in either orientation, where  $R^3$  is as defined above;


each pair of  $A^1-A^n$  and  $B^1-B^n$  are selected such that:

(a) A is a group of formula (IIa), (IIb) or (IIc) and B is N or R<sup>3</sup>N<sup>+</sup>; or


(b) A is a group of formula (IIId) and B is CH;




(IIa)



(IIb)



(IIc)



(IIId)

where:

X is O, S, Se, NR<sup>3</sup>, CH<sub>2</sub> or C(CH<sub>3</sub>)<sub>2</sub>;

Y is a single bond, O, S or NR<sup>4</sup>;

each of p and q is zero or an integer from 1 to 5, the sum p+q being not more than 10;

each of r and s is zero or an integer from 1 to 5, the sum r+s being not more than 10;

each R<sup>1</sup> and R<sup>2</sup> is independently selected from the group consisting of hydrogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl which may be hydroxy- or alkoxy- or alkylthio-substituted, hydroxy, alkoxy, alkylthio, amino and halogen;

each of G<sup>1</sup>-G<sup>n-1</sup> is -NR<sup>3</sup>CO-, -NR<sup>3</sup>CS-, -NR<sup>3</sup>SO- or -NR<sup>3</sup>SO<sub>2</sub>-, in either orientation, where R<sup>3</sup> is as defined above;


Q is -CO<sub>2</sub>H, -CONR'R'', -SO<sub>3</sub>H or -SO<sub>2</sub>NR'R'' or an activated derivative of -CO<sub>2</sub>H or -SO<sub>3</sub>H; and

I is -NHR'''R'''' or -NR'''C(O)R''''', where R', R'', R''' and R'''' are independently selected from the group consisting of hydrogen, alkyl, amino protecting




groups, reporter ligands, intercalators, chelators, peptides, proteins, carbohydrates, lipids, steroids, nucleosides, nucleotides, nucleotide diphosphates, nucleotide triphosphates, oligonucleotides, oligonucleosides and soluble and non-soluble polymers.


8. A macromolecule of claim 1 wherein each of said PNAs comprises a compound of the formula IIIa, IIIb or IIIc:



(IIIa)



(IIIb)



(IIIc)

wherein:

each L is independently selected from the group consisting of hydrogen, phenyl, heterocyclic moieties, naturally occurring nucleobases, and non-naturally occurring nucleobases;

each R' is independently selected from the group consisting of hydrogen and the side chains of naturally occurring alpha amino acids;

n is an integer from 1 to 60;

each of k, l, and m is independently zero or an integer from 1 to 5;

p is zero or 1;

R<sup>h</sup> is OH, NH<sub>2</sub> or -NHLysNH<sub>2</sub>; and

R<sup>i</sup> is H or COCH<sub>3</sub>.

9. A macromolecule of claim 8 where each of said PNAs comprise a compound having formula (IIIa)-(IIIc) wherein each L is independently selected from the group consisting of the nucleobases thymine (T), adenine (A), cytosine (C), guanine (G) and uracil (U), k and m are zero or 1, and n is an integer from 1 to 30, in particular from 4 to 20.

10. A compound of claim 9 wherein:

said DNA includes at least three of said 2'-deoxynucleotides linked together in a sequence:

each PNA includes at least two peptide nucleic acid subunits; and

said 2'-deoxynucleotides are joined via phosphodiester, phosphorothioate or phosphorodithioate linkages.

11. A macromolecule of claim 1 wherein each of said PNAs is covalently bound to said DNA with an amide, amine or ester linkage.


12. A macromolecule of the structure:  
PNA-(amide link)-DNA-(amide link)-PNA:

wherein:

said DNA comprises at least one 2'-deoxynucleotide;

each of said PNAs comprise at least one peptide nucleic acid subunit; and

each of said amide links includes an amide linkage of the structure:



13. A method of treating an organism having a disease characterized by the undesired production of a protein, comprising contacting the organism with a macromolecule that has structure PNA-DNA-PNA and that includes a sequence of nucleobases capable of specifically hybridizing to a strand of nucleic acid coding for said protein, wherein:

said DNA includes at least one nucleotide having a 2'-deoxy-erythro-pentofuranosyl sugar moiety covalently bound to one of said nucleobases; and

each of said PNAs include at least one peptide nucleic acid subunit having a covalently bound nucleobase.

14. A method of claim 13 wherein said nucleotide is a phosphorothioate nucleotide.

15. A method of claim 13 wherein said nucleotide is a phosphorodithioate nucleotide.

16. A method of claim 13 wherein said nucleotide is a phosphodiester nucleotide.

17. A pharmaceutical composition comprising a pharmaceutically effective amount of a macromolecule of claim 1 and a pharmaceutically acceptable diluent or carrier.

18. A method of *in vitro* modification of sequence-specific nucleic acid, comprising contacting a test solution containing RNase H and said nucleic acid with a macromolecule of claim 1.

19. A method of enhancing polynucleotide hybridization and RNase H activation in a organism, comprising contacting the organism with a macromolecule of claim 1, wherein:

said macromolecule has a sequence of nucleobases capable of specifically hybridizing to a complementary strand of nucleic acid; and

some of said nucleobases are located on the PNA portions of said macromolecule and some of said nucleobases are located on the DNA portion of said macromolecule.

20. A method of treating an organism having a disease characterized by the undesired production of a protein, comprising contacting the organism with a compound of claim 1.

21. A method of *in vitro* modification of sequence-specific nucleic acid, comprising contacting a test solution containing RNase H and said nucleic acid with a compound of claim 10.

22. A method of treating an organism having a disease characterized by the undesired production of a protein, comprising contacting the organism with a compound of claim 10.

23. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of claim 10 and a pharmaceutically acceptable diluent or carrier.

١٠٠

١٠٠

١٠٠

FIGURE 1






FIGURE 2



Ac-Gly-TTC<sup>Z</sup>TC<sup>Z</sup>G<sup>Z</sup>C<sup>Z</sup>-COOH,  
coupling agent



(10) K<sub>2</sub>CO<sub>3</sub>  
(11) conc. NH<sub>4</sub>OH  
(12) Cat. Hydrogenation




FIGURE 3






FIGURE 4




Figure 1 consists of 12 scatter plots, labeled (a) through (l), each showing the relationship between a specific variable and the number of children. The variables are: (a) Age, (b) Education, (c) Income, (d) Employment, (e) Health, (f) Religion, (g) Ethnicity, (h) Marital status, (i) Family size, (j) Urban/rural, (k) Migration, and (l) Fertility rate. Each plot shows a positive correlation between the variable and the number of children.





FIGURE 6



DOCKET NO.: ISIS-1236

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Phillip Dan Cook

Serial No.: N/A

Group Art Unit: N/A

Filed: Herewith

Examiner: N/A

For: PNA-DNA-PNA CHIMERIC MACROMOLECULES

**BOX SEQUENCE**

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231


Dear Sir:

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE  
WITH 37 CFR §§ 1.821 THROUGH 1.825**

- (XX) I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
- ( ) I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.
- ( ) I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
- ( ) I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages \_\_\_\_\_. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.
- ( ) I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.

( ) I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.85(d), contains identical data to that originally filed.

Date: November 24, 1993

  
\_\_\_\_\_  
Signature  
John W. Caldwell  
Registration No. 28,937

WOODCOCK WASHBURN KURTZ  
MACKIEWICZ & NORRIS  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
(215) 568-3100

2025-11-24 14:00:00